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Numerous studies have contributed to the induction of pluripotency in an abundance of cell 
types; however, transfection techniques and efficiency have yielded undesirable outcomes. 
Traditionally, the use of viral vectors as a mode of transmission has proven to be efficient in the 
induction of pluripotency transcription factors in mammalian cells. The increasing concern is 
random insertion of viral components within the host genome due to the viral mode of 
replication. The delivery of messenger RNA by cationic lipid delivery vehicles circumvents the 
viral concerns and provides an efficient and safe mode of reprogramming. Synthetic mRNA can 
be used to initiate endogenous gene expression while maintaining cellular viability in bovine 
somatic cells. In this study, bovine fetal fibroblast cells were initially transfected with In Vitro 
Transcribed (IVT) RNA expressing Green Fluorescent Protein (GFP) to determine adequate 
transfection parameters. Mammalian expression vectors, encoded with either GFP or 
pluripotency associated transcription factors OCT4, SOX2, c-MYC, or KLF4, were obtained 
from a plasmid repository and used as IVT templates. The mRNA was produced in vitro to 
include a 5’ cap as well as a 3’ polyA tail in order to mimic in vivo mRNA packaging. Primary 
cultures of bovine fetal fibroblasts were transfected with ivtRNA by way of a cation lipid 
delivery vehicle, Lipofectamine, for endocytotic uptake. This process allows the mRNA to 
bypass the phospholipid bilayer and enter the cell. The incorporation of modified bases during 
the in vitro transcription process was adopted to reduce cell immune response. Addition of small 
molecules to enhance the reprogramming process was evaluated as well.  The success of ivtRNA 
transfection in bovine fetal fibroblast cells was determined through the measurement of cellular 
viability, mean fluorescence by flow cytometry under different concentrations of mRNA, and 






Different stem cell types have been described including Adult Stem Cells (ASCs), 
Embryonic Stem Cells (ESCs), Induced Pluripotent Stem Cells (iPSCs) and RNA-Induced 
Pluripotent Stem Cells (RiPSCs). Adult stem cells can be found in various types of adult, or non-
embryonic, tissues and give rise to particular cell lines. The natural purpose of these cells is to 
replace diminishing cells during growth or injury (Odorico et al., 2001). Embryonic stem cells 
arise from the inner cell mass (ICM) of a developing blastocyst and can give rise to all cell 
lineages of the fetus proper; all three major germ layers are produced. ESCs can no longer 
differentiate into extra-embryonic, or placental, tissue (Odorico et al., 2001). The third type of 
stem cells is known as induced pluripotent stem cells or iPSCs. These cells are derived from 
reprogrammed somatic or differentiated cells, and can be utilized in place of ESCs to eliminate 
the destruction of embryos while harvesting the ICM. These cells closely resemble the ES cells 
in many aspects including the ability to differentiate into different cell-lineages and proliferation. 
RiPSCs are simply a type of iPSCs where synthetic in vitro transcribed messenger RNA is 
utilized for the induction for reprogramming. Induced pluripotent stem cells have become a very 
important tool for the scientific community to study the cellular differentiation process, genetic 
manipulations, and regenerative medicine. 
Induced pluripotent stem cells can be obtained by an extended list of reprogramming tools. The 
reprogramming of somatic cells can be achieved through the delivery of exogenous transcription 
factors that stimulate genetic activity similar to that of embryonic stem cells. These exogenous 
transcription factors include, but are not limited to OCT4, SOX2, NANOG, c-MYC and KLF4 
(Takahashi and Yamanaka, 2006). The introduction of these previously silenced embryonic 
transcription factors can up-regulate their own endogenous expression. While, theoretically, the 
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increased expression should be easily attainable, there are numerous cellular hurdles to 
overcome. These hurdles tend to lead to differences in efficiency and at times successes of 
various modes of cellular reprogramming to pluripotency.  These modes of reprogramming 
utilize various cellular processes to increase endogenous expression of known pluripotency 
factors. Viral transduction is commonly used in research as the mode of choice for the delivery 
of these factors. The virus encoding the desired sequence is incubated with the target cells to be 
reprogrammed. The cells are reprogrammed quite efficiently and have desirable results, though 
the random insertion of viral particles into the host genome remains undesirable. Viruses with 
alternate modes of replication have been used to minimize this random insertion with mixed 
results, including incomplete reprogramming (Takahashi and Yamanaka, 2006; Fusaki et al., 
2009). There have been other attempts to avoid this random insertion, such as the addition of 
specific proteins to the target cells (Kim et al., 2009a; Zhou et al., 2009; Cho et al., 2010). While 
this circumvents the insertion issue, it can be a difficult process to achieve due to the difficult 
purification processes. Synthetic messenger RNA transfection has the ability to avoid both 
random insertion into the host genome and rigorous purification protocols.   
Synthetic RNA transfection has been an invaluable tool in understanding the mammalian 
genome due to its ability to deliver exogenous protein without mutagenic effects caused by 
double stranded DNA. A common problem associated with the introduction of exogenous 
mRNA into mammalian cells is the stimulated interferon response. This innate immune response 
can be avoided with the addition of modified bases during the in vitro transcription process of 
synthetically derived mRNA (ivtRNA). The bases cytidine triphosphate (CTP) and uridine 
triphosphate (UTP) are replaced with 5-methylcytidine-5’-triphosphate (5-Methyl-CTP) and 
pseudouridine-5’-triphosphate (Pseudo-UTP) during in vitro transcription. Cellular 
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reprogramming is achieved by the delivery of this ivtRNA into the cytoplasm. Previous cellular 
reprogramming experiments lacking modified bases resulted in increased toxicity and decreased 
cellular viability, which lead to the incorporation of modified bases (Warren et al., 2010). The 
decreased immune response by the inclusion of modified bases may be advantageous in a variety 
of applications, from the introduction of TALENS or zinc finger nucleases for genomic editing 








































Embryonic Stem Cells 
 
ESCs are derived from the inner cell mass (ICM) of a developing blastocyst. These cells 
will eventually differentiate into hundreds of various cell types that will unify to form an entire 
fully functional organism. The genetic programming needed to differentiate into a completely 
functional cell type is contained in each of these embryonic stem cells. There are very specific 
epigenetic triggers that must occur to determine which path is to be followed. The primary 
distinction of embryonic stem cells from trophectoderm cells is the change in cellular pathways 
and expression. The inner cells of the blastocyst receive cell surface signals impeding cellular 
blocks preventing pluripotent transcription factor Oct4 (Gilbert, 2010). The pluripotency of these 
embryonic stem cells is dependent on Oct4 gene expression. When Oct4 expression is decreased 
or prevented, differentiation pathways are activated.   
Distinctive Properties of Embryonic Stem Cells 
 
Embryonic stem cells possess a truly unique quality that allows complete differentiation 
of a cell down numerous developmental pathways. This quality is diligently sought after to cure 
and/or treat disease and further the success of regenerative medicine. This quality is known as 
pluripotency. Pluripotency can be defined as the ability of a cell to give rise to all three germ 
layers of the embryo proper while not producing the cells confined to extra-embryonic, placental 
tissue. Cells that that have the ability to become both the embryo proper and the extra-embryonic 
tissue are known as totipotent. The cells that make up the zygote are totipotent and will 
eventually segregate into two specific cell types: ICM and trophoblast cells.  
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Stem cells possess another interesting quality of self-renewal. Few cells possess this 
remarkable feature. Many cells have a predetermined number of cell divisions and will 
eventually terminally differentiate; they will no longer self-renew. An example cell type 
expressing terminal differentiation is neuronal cells. These cells will develop and differentiate 
down a particular path and arrest at a pre-determined point. If damaged, these cells cannot repair 
themselves to be made new again. Regenerative medicine had focused on therapeutic care 
involving such damage, like spinal injuries, for some time now. The desire to capture these 
qualities and facilitate safe and efficient reproduction has been sought after by many research 
institutions. The study of numerous diseases as well as normal zoological development is made 
possible by the production of cells containing these qualities. 
Mouse ESCs were first isolated and characterized in 1981. There were two characteristics 
of interest: infinite proliferation, and the ability develop into various specialized cell types 
(Evans and Kaufman (1981). Human ESCs were first isolated in 1998 by James Thompson at the 
University of Wisconsin. He utilized the characteristics developed previously to verify that the 
cells he had isolated were in fact ESCs. The cells possessed the ability to both infinitely 
proliferate and develop into various cell types (Thomson et al., 1998). 
The disadvantage to possessing these cells is that in order to obtain them, the embryo 
harvested for embryonic stem cell retrieval is ultimately destroyed. Once the inner cell mass is 
removed from the blastocyst, it can no longer proceed with normal development to form an 
organism. This area of medicine has, of course, developed attention and ethical concerns in both 
the public and private sectors. Media and political attention have caused a decrease in research 
utilizing human embryos. The drive to eliminate embryo destruction led to the development of 
induced pluripotent, or reprogrammed cells.    
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Adult Stem Cells 
Adult stem cells (ASCs) are present in the body of an individual and are used to replace 
cells lost due to growth or damage (Stein, 2011). Some tissues in the body have an abundant 
ability to self-renew, indicating an increased source of adult stem cells for replenishment; others 
do not regenerate as actively (Wagers and Weissman, 2004). These adult stem cells can be found 
in many tissues such as bone, marrow, skin, muscle, and fat. These cells are referred to as “adult” 
but are not restricted adult organisms and can occur in a variety of non-embryonic tissue.  
A specialized form of ASCs used in research is hematopoietic (HSCs) or Mesenchymal 
stem cells. A single cell derived from bone marrow has the ability to give rise to different blood 
cell types (Till and McCulloch, 1961). ASCs can be characterized as multi-, oligo-, or unipotent, 
and can give rise to a limited number of cells—and, in some cases, only one very specific cell 
type (Wagers and Weissman, 2004). These cells are usually restricted to a particular cell type or 
group from which they are located, and have been the reason for limited clinical applications of 
ASCs.  
Induced Pluripotent Stem Cells 
Somatic or differentiated cells have the ability to be reprogrammed into a less 
differentiated, pluripotent-state and are referred to as induced pluripotent stem cells or iPSCs. 
These cells become like embryonic stem cells—regaining the ability to proliferate—and can be 
stimulated to become other cell types. IPSCs are a conduit for reprogramming methods resulting 
in a desired cell type. There are numerous epigenetic modifications that take place when a cell 
line transforms from a terminally differentiated state, such as a somatic cell to an embryonic-
cell-like state. The cells gain the ability to change from unipotent to pluripotent: a precursor to 
many cell types instead of just one. The mechanisms within cellular reprogramming are intricate  
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and somewhat illusive. The understanding and manipulation of these mechanisms provide an 
array of scientific benefits. Attempts have been made in several species to reprogram somatic 
cells to pluripotency and become embryonic stem cell-like (ES cell-like) colonies. This feat was 
first completed in 1981 by culturing the inner cell mass of mouse embryos (Evans and Kaufman, 
1981). Later, Yamanaka and colleagues established the known four-factor cocktail of 
transcription factors—Oct3/4, Sox2, c-Myc, and Klf4—needed to induce pluripotency in mice 
and human fibroblasts (Takahashi and Yamanaka, 2006; Takahashi et al., 2007). Due to the 
apparent conservation of the sequences, the induction of pluripotency has been successful in 
other species such as rat, pig, rhesus monkey, rabbit, and canine (Liu et al., 2008; Esteban et al., 
2009; Ezashi et al., 2009; Liao et al., 2009; Honda et al., 2010; Shimada et al., 2010). Bovine 
embryonic fibroblasts recently have been reprogrammed to pluripotency utilizing a retroviral 
vector in 2011(Han et al., 2011). The viral transfection process is very efficient, but has caused 
concern in the domestic animal industry due to its possible integration into the genome. Attempts 
are being made to eliminate viral components in the induction of pluripotent stem cells. 
RNA Induced Pluripotent Stem Cells   
A novel approach to eliminate the use of viral vectors in pluripotency induction is the use 
of in vitro transcribed mRNA (ivtRNA) as the pluripotency stimulating molecule. This ivtRNA 
encodes one of the known pluripotent transcription factors and can be combined with others for 
increased efficiency of induction. The ivtRNA is then encapsulated within a cationic lipid 
delivery vehicle for enhanced delivery into the cell. The host cell can then produce the 
transcription factor while eliminating the fear of viral contaminants. RNA-induced pluripotent 
stem cells can safely deliver the much sought-after qualities of ESCs while simultaneously 
eliminating the destruction of embryos.  
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Benefits of Stem Cells in Research 
Stem cells possess the ability to differentiate into separate cell lineages and can 
contribute greatly to the scientific community. The benefits of safe iPSCs are numerous.  One of 
the benefits is regenerative medicine, which is designed to replace lost or damaged cells due to 
illness or injury (Hipp and Atala, 2008). The benefits affect human therapeutic applications, 
alleviated ethical concerns with the destruction of embryos for stem cell harvest, provision of a 
higher quality and less differentiated cell to be used for SCNT, and higher quality genetically 
modified livestock with no viral carryover. The ES-like colonies can be developed with both 
efficient production and safe transmission lacking integration into the host genome. The 
elimination of viral integration and increased colony production are useful research goals for 
commercial applications. 
Gene Expression of Embryonic Stem Cells 
OCT4 
There are numerous pluripotent transcription factors associated with embryonic stem 
cells. These include OCT4, SOX2, c-MYC, and NANOG. OCT4 is a part of the POU (Pir-Oct-
Unc) transcription factor family that regulates gene expression by binding to a specific domain 
containing an AGTCAAAT consensus sequence (Schöler et al., 1991; Pesce and Schöler, 2001; 
Jin et al., 2002). Many sources suggest the presence of OCT4 is required to obtain any of the 
other transcription factors, and is responsible for maintaining pluripotency (Niwa et al., 2000; 
Pesce and Schöler, 2001; Jin et al., 2002; Babaie et al., 2007). Overexpression of OCT4 can 
stimulate ESCs to differentiate into endoderm or mesoderm type cells (Niwa et al., 2000; 
Rodriguez et al., 2007) while reduced expression induces trophectoderm differentiation (Niwa et 
al., 2000; Hay et al., 2004; Matin et al., 2004; Zaehres et al., 2005; Babaie et al., 2007). The 
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diagram below illustrates the changes in OCT4 expression throughout development (Jin et al., 
2002). Positive OCT4 expression 
 
 Figure 2.1 OCT4 Expression During Development (Jin et al., 2002) 
can be seen in the zygote and morula, but later expression becomes isolated to the ICM of the 
blastocyst.  The outer trophoblastic cells are expected to test negative for OCT4. Once ESCs 
differentiate into separate lineages, the OCT4 expression is suppressed.  
Due to the importance of OCT4 in maintaining pluripotency, it is crucial to limit its 
expression when cells require differentiation instead of proliferation. “Oct4 activity must be 
tightly regulated to ensure the continuity of the germline and proper differentiation of various 
tissues and organs” (Jin et al., 2002). OCT4 works in conjunction with other transcription factors 
to assist in maintaining pluripotency via stimulation and repression of important genes within the 
genome. OCT4 is a part of the POU (Pir-Oct-Unc) transcription factor family that regulates gene 
expression by binding to a specific domain containing an AGTCAAAT consensus sequence 





Another transcription factor proven important in early development of ESCs is SOX2. 
This factor plays a role in maintaining pluripotency but can also participate in the differentiation 
of ESCs. SOX2 expression is not restricted to the inner cell mass and epiblast, but is also found 
to be expressed in neural tissues, extra-embryonic ectoderm, gut endoderm, esophagus, and 
trachea (Wood and Episkopou, 1999; Avilion et al., 2003; Williamson et al., 2006; Adachi et al., 
2011).  Prior to implantation, SOX2 plays a significant role in the formation of trophectoderm 
and neural development (Avilion et al., 2003; Kelberman et al., 2006; Taranova et al., 2006). 
Although expression has been reported in numerous locations, SOX2 continues to play a 
fundamental role in maintaining the inner cell mass. Overexpression of SOX2 can lead to non-
specific lineage differentiation, neuronal formation, and/or massive cell death (Mitsui et al., 
2003; Zhao et al., 2004; Kopp et al., 2008; Adachi et al., 2011). If repressed, SOX2 can induce 
the formation of trophectoderm (Masui et al., 2007).  An impediment in the continuation of the 
ICM maintenance as well as defective development of trophoblast cells was observed in Sox2-
deficient mice (Avilion et al., 2003). These observations suggest the widely diverse role of 
SOX2 in maintenance and differentiation during the earliest stages of development. 
NANOG 
There is another very important transcription factor that exists within the pluripotency 
network known as NANOG. This transcription factor is essential in blocking differentiation in 
embryonic stem cells. The development of ESCs occurs in cycles of expansion, or proliferation, 
and differentiation. There are specific signals that must be present for the cell to follow one path 
or another. The combined expression of OCT4 and SOX2 transcription factors is thought to 
activate NANOG by binding to the NANOG promoter thus activating transcription. NANOG 
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gains the ability to, in turn, further activate itself, OCT4, and SOX2 (Chickarmane et al., 2006; 
Wu et al., 2006; Storm et al., 2007; Takao et al., 2007). A continuous loop is formed containing 
numerous interweaving pathways that would both activate and repress expression in a very 
specific manner. A recent paper suggests possible auto-repression of NANOG to regulate 
transcription switching independent of OCT4 and SOX2 (Navarro et al., 2012). It is suggested 
that “in contrast to the accepted model, [there is] a negative correlation between the level of 
Nanog mRNA and protein…and the level of transcription of the endogenous Nanog 
locus…suggesting that NANOG negatively affects transcription [of the] Nanog gene” (Navarro 
et al., 2012).  Once NANOG expression is repressed, its absence stimulates its own production; 
but when in abundance, NANOG again undergoes auto-repression through unknown binding 
sites (Navarro et al., 2012).   OCT4 and SOX2 have been shown to activate NANOG 
transcription through joint binding, but the OCT4/SOX2 stimulation pathway may be 
independent of the NANOG-Nanog-induced pathway (Navarro et al., 2012). 
c-MYC 
In 2006, Takahashi and Yamanaka isolated four transcription factors needed to stimulate 
pluripotency in somatic cell reprogramming. These four factors were OCT4, SOX2, NANOG, 
and c-MYC. The first three are known to have a close relationship for intertwining activation and 
repression of one another, as previously stated. Transcription factor c-MYC plays a role in the 
efficiency in which these factors can induce pluripotency in somatic cells, but it is not actually 
required for the process to take place (Nakagawa et al., 2008; Wernig et al., 2008). However, c-
MYC is a known oncogene that has the potential to become mutated and stimulate infinite 
proliferation. It is this fact that guides researchers to refine an efficient production process for the 
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induction of pluripotency that excludes the c-MYC transcription factor from the reprogramming 
cocktail for fear of inducing cancer.  
KLF4 
The Kruppel-like factor 4 is a key factor in cellular reprogramming to pluripotency 
(Evans et al., 2007). This factor is tightly bound to the OCT4 and SOX2 synergistic network of 
signaling pathways and influences the production of  the much needed transcription factor, 
Nanog (Wei et al., 2009). KLF4 can play the role of both an activator and repressor of the 
transcriptional pathway to pluripotency by regulating proliferation and differentiation (Evans et 
al., 2007). This transcription factor includes three zinc fingers at the C terminus that play a 
crucial role in the activation and transcription of the Nanog promoter (Wei et al., 2009). KLF4 
has been reported to be a tumor suppressor within gastrointestinal cancers (Dang et al., 2000). It 
is interesting to note, however, that there are negative forms of KLF4 that can suppress or 
decrease cellular reprogramming to pluripotency. Studies have reported that the introduction of 
these negative forms can significantly reduce cellular reprogramming (Wei et al., 2009). 
Numerous research strategies attempt to eliminate KLF4 from the reprogramming cocktail due to 
its identification as an oncogene associated with breast cancer (Foster et al., 2000). This factor 
has both tumor-suppressive and tumor-stimulatory characteristics and may lead to its final 
elimination within the reprogramming cocktail, but its intimate relationship with pluripotency 
factors OCT4 and SOX2 will secure its position in many reprogramming protocols.   
Somatic Cell Nuclear Transfer 
The process of somatic cell nuclear transfer fuses an enucleated oocyte with a fully 
differentiated somatic cell to produce an embryo, and even live offspring (Gurdon et al., 1958; 
Campbell et al., 1996; Wilmut et al., 1997). The donor cell must undergo a series of epigenetic 
13 
 
changes to become reprogrammed into an embryonic state when placed inside or fused with an 
oocyte. Once the cell has been reprogrammed, developmental processes can then occur to 
develop cells of many lineages. If a donor cell population to be used for SCNT has already been 
reprogrammed, it could jumpstart the developmental process, thus increasing efficiency.  
Early experiments tested the theory of cells maintaining the genetic material required to 
support different cellular lineages. This was evaluated by transplanting nuclei from living cells 
into the eggs of frogs (Briggs and King, 1953; Gurdon et al., 1958; Gurdon, 1962a). The birth of 
Dolly in 1997 exhibited the idea that a differentiated cell maintained the genetic ability to 
support the complete development and maturation of an adult mammal through the process of 
somatic cell nuclear transfer  (Wilmut et al., 1997). The environment within the oocyte supports 
the epigenetic reprogramming of the transferred nucleus and has the potential to become 
totipotent, developing into a fully developing embryo. The concern in this process is incomplete 
cellular reprogramming as the transferred nucleus undergoes epigenetic modifications. These 
early incomplete reprogramming processes often lead to problematic placental development, 
large offspring syndrome, and shorter life span (Yang et al., 2007; Gurdon and Wilmut, 2011). In 
earlier amphibian experiments, the success of the development process was thought to be 
influenced by the donor cell for transfer (Briggs and King, 1960). The earlier in the 
developmental pathway a donor cell is harvested, the more normality exhibited in the transfer 
development (Briggs and King, 1957; Gurdon, 1962b). The concern leads to the requirement of a 
less differentiated cell as the nuclear donor for somatic cell nuclear transfer. This less-
differentiated cell can be obtained from embryonic cells, though they may not be available for 
isolation.  A completely reprogrammed somatic cell exhibiting embryonic stem cell 
characteristics and gene expression is thought to be an alternate source of nuclei for transfer. It is 
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at a less-differentiated state and requires less reprogramming stimulation by the oocyte. 
Efficiency of SCNT and decrease in problematic developmental concerns has the potential to be 
achieved with this previously reprogrammed nucleus.  
Reprogramming by Viral Transfection 
 
While true embryonic stem cells are isolated from the inner cell mass of the embryo, 
numerous processes have been defined to obtain cells whose characteristics are nearly identical. 
Cellular reprogramming by viral transduction is the most accepted method for reprogramming. 
The viral particles are easily accessible and can be altered for very specific uses. The viral 
particles encoding desired sequences are introduced to the cell culture where they are taken up 
by the cells. The sequences are integrated into the genome and are expressed by the cell to allow 
reprogramming. When compared to mRNA transfection this approach is characterized by a 
considerable decline in workload. The transduction is conducted once or twice at the beginning 
of the reprogramming trial compared to daily mRNA transfections during the weeks of cellular 
reprogramming. The daily transfections not only are more labor intensive, but also increase the 
likelihood of contamination with excessive handling. The viral method demonstrates increased 
efficiency when compared to other reprogramming methods, though efficiency can be measured 
in various ways. The total number of cells reprogrammed from the starting material remains 
around 1% but can be increased considerably compared to other methods. According to a recent 
paper, the mRNA reprogramming method is equally or more efficient than the accepted viral 







Problems Associated with Viral Transfection 
 
The possible integration into the host genome is the major concern in viral-mediated 
reprogramming. The many human and/or domestic animal applications do not allow genetic 
carry-over of viral material. The numerous studies performed utilizing viral reprogramming 
generated mixed conclusions concerning the removal of viral particles with extended culture. 
Viral particles are difficult to completely eliminate from the cell lineage.  
DNA-Free Transfection Methods; Cell-Penetrating Peptide Moieties and RNA-Based Viral 
Systems 
 
The mode of transmission most commonly utilized is viral transmission due to its 
increased efficiency in the production of pluripotent stem cell lines. Other modes include, but are 
not limited to, serial protein transduction (Kim, D. et al.,2009; Zhou et al., 2009), non-integrating 
Sendai virus (Fusaki et al., 2009), chemical induction paired with a single transcription factor 
(Li, Y. et al., 2011), and the novel approach of synthetic modified mRNA delivery (Warren et 
al., 2010). These methods all utilize different mechanisms for successful cell integration. The 
method of transmission to be utilized commercially or on a grand scale should be efficient in 
reprogramming and formation of iPSC colonies, as well as safe for the host genome post-
transmission. The viral method is highly efficient, but it is the least safe of all methods. The 
possible integration into the host genome is of the greatest concern, especially if the cells are to 
be used in human therapeutic treatments or in the formation of genetically modified livestock. 
The random insertion of the viral components into the host genome carries numerous possible 
genetic complications. Protein transduction is safe as it pertains to the host genome, but is 
difficult to harvest and purify in quantities required for reprogramming procedures (Zhou et al., 
2009). The Sendai virus has an RNA-based life cycle and theoretically should not integrate into 
the host genome. However, the purification processes are very rigid to ensure no viral carryover. 
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This harsh process can decrease the overall efficiency of the Sendai virus as a carrier vehicle 
(Fusaki et al., 2009).  However, synthetic mRNA can be directly administered to induce 
pluripotency without integration into the host genome and provide efficient iPSC production 
(Warren et al., 2010).  
In Vitro Transcribed Messenger RNA Delivery for Reprogramming 
 
Previous research has focused on inducing pluripotency of somatic cells to avoid the 
destruction of embryos due to its obvious ethical concerns. The addition of transcription factors 
normally present in the embryonic cells is fundamental to the reprogramming process. The 
methods of including these factors have varied from viral transmission, bacterial plasmid 
introduction, and addition of cellular extracts in culture. While all have been successful in 
developing pluripotent stem cells, growing concerns center on factor carry-over from these 
methods. The addition of synthetically derived messenger RNA encoding known pluripotent 
transcription factors can eliminate these genetic concerns. Desired sequences are synthesized 
from a template and packaged to ensure acceptance by the target cell. The transcripts contain a 5’ 
guanosine cap analogue and 3’ polyadenylation similar to the packaging acquired in vivo for 
translation. The in vitro transcribed transcript, ivtRNA, is delivered into the cell by either lipid-
mediated delivery vehicle or electroporation. Once the sequence crosses the cell membrane, it 
can be taken up by the cellular machinery for translation. The increase in desired transcription 
factors has the ability to increase or decrease endogenous production. Repeated transfections 
using exogenous synthetic messenger RNA is required to achieve this effect. The encouraging 
characteristic of ivtRNA is that it does not integrate into the host genome and does not carry over 




Enhanced Reprogramming Using Small Molecules 
Reprogramming of somatic cells has proven to be inefficient, leading to the discovery of 
small molecules for enhanced reprogramming. The small molecules can either replace current 
transcription factors, or simply be added to the culture medium for increased reprogramming 
efficiency. The replacement of oncogenic transcription factors such as c-Myc and Klf4, as well 
as the elimination of viral vectors, can be useful in therapeutic applications. The eventual 
elimination of possible genetic carryover and integration is the goal of small molecule 
reprogramming methods. A recent study may have overcome this barrier by reprogramming 
mouse somatic cells to pluripotency by small molecules alone (Hou et al., 2013). 
Small molecules have the potential to stimulate or inhibit critical developmental 
pathways for the induction or maintenance of pluripotency, and are typically organic compounds 
measuring less than 500 Daltons in size. These small molecules can be genetic factors, signaling 
molecules, and chemical inhibitors that can replace and/or enhance the predetermined core 
transcription factors required for reprogramming.  Some non-oncogenic transcription factors can 
replace oncogenic transcription factors in reprogramming. Klf4 and c-Myc can be replaced with 
Nanog and Lin28 respectively (Yu et al., 2007).  Certain cell types readily express core 
transcription factors endogenously and require less exogenous stimulation to achieve 
reprogramming. Neural progenitor cells (NPCs) contain endogenous Sox2 in relatively high 
levels and can be reprogrammed to pluripotency without addition of exogenous Sox2 
transcription factors (Eminli et al.; Duinsbergen et al., 2008; Jeong Beom et al., 2008).  
The addition of small molecules can enhance a reprogramming procedure by affecting 
various cellular processes. One process commonly targeted is the G9a histone methyltransferase 
pathway (HMT). Histone modifications such as lysine methylation can greatly affect chromatin 
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accessibility during mitosis and transcription. These modifications can have various 
developmental effects. Specifically, histone H3 Lysine9 (H3K9) methylation is responsible for 
chromatin repression for developmentally important genes and is catalyzed by G9a HMT. 
According to a previous study, “the euchromatic H3-K9 methylation regulated by G9a is 
involved in the transcriptional silencing of developmentally regulated genes” (Tachibana et al., 
2002). The inhibition of G9a HMT can lead to the up-regulation of pluripotent transcription 
factors previously silenced. DZNep, a S-adenosyl homocysteine (SAH) hydrolyse inhibitor, has 
been reported to increase reprogramming efficiency when combined with other small molecules 
(Hou et al., 2013). The increase in SAH interferes with the lysine methylation process required 
for repression.  One small molecule that has been shown to inhibit G9a histone methyltransferase 
(HMT) is BIX-01294, which does not compete with cofactor S-adenosylmethionine (SAM) (Shi 
et al., 2008). BIX-01294 has been reported to enhance cellular reprogramming to pluripotency 
and has the ability to replace Sox2  when reprogramming mouse neural progenitor cells (NPCs) 
(Shi et al., 2008). The chemical inhibitor, NuP0148 (NuPotential, Baton Rouge, LA), inhibits 
G9a HMT by binding to the S-adenosylmethionine (SAM) binding site within the enzyme. This 
inhibits the transfer of a methyl group to the histone lysine tail. The obstruction of the SAM 
binding site may be advantageous to simply increase the ratio of SAH to SAM present within the 
system. Developing small molecule inhibitors requires specificity and the SAM binding site 
seems to be an exceptionally good landscape. This inhibition then leads to increased 
reprogramming by reactivating the previously silenced Oct4 heterochromatin region. The 




In addition, glycogen synthase kinase 3 (GSK3) and mitogen-activated protein kinase 
(ERK1/2) pathways can be inhibited to promote cellular reprogramming. The combined 
inhibition of these pathways can lead to reactivation and stabilization of the core pluripotent 
transcriptional circuitry required for differentiated cellular reprogramming. GSK3 inhibitor 
CHIR99021 combined with ERK1/2 inhibitor PD0325901 has been shown to enhance 
reprogramming to pluripotency (Silva et al., 2008). 
Safety and Efficiency of Reprogramming to Pluripotency: Future Outlook 
 
Pluripotency can be achieved by numerous reprogramming methods, all of which result 
in different yields and standards of efficiency. The following diagram has been modified to 
illustrate the position these methods place in terms of safety and efficiency (González et al., 
2011). Efficiency is not a term uniformly agreed upon, but generally refers to a yield of colonies 
from a limited amount of resources and time. Safety refers to the genetic carryover associated 
with the reprogramming method. The viral methods have proven to be the most efficient in terms 
of colony yield, but have yet to completely eliminate genetic carryover. Methods of 
reprogramming such as the addition of proteins associated with pluripotency are quite safe. 
Concern with genetic integration and long-term expression is absent; however, the complicated 
processes associated result in low yield. A previous study utilized synthetic messenger RNA, or 
ivtRNA, as a reprogramming tool with efficiency results comparable to viral methods (Warren et 
al., 2010). The lack of genetic integration and/or random insertion places this reprogramming 





Figure 2.2 Efficiency and Safety Comparison of Cellular Reprogramming Methods (modified 


































RESPONSE OF BOVINE FETAL FIBROBLASTS TO PLURIPOTENCY 
INDUCTION WITH IN VITRO TRANSCRIBED MRNA 
 
Introduction 
Cellular reprogramming can be achieved by the delivery of mRNA into a biological 
system. The introduction of RNA can either up-regulate or “knock-down” gene expression in a 
very specific manner. The introduction of exogenous mRNA eliminates the transcription process 
required with the introduction of DNA into the cell. The new sequence can be delivered into the 
cytoplasm for immediate translation. There are two methods of mRNA delivery: electroporation 
and cationic lipid-mediated delivery vehicles (Van Tendeloo et al., 2001; Audouy et al., 2002). 
Electroporation is the process in which genetic material is introduced into the cell by pores in the 
cytoplasm caused by electric pulses. This process efficiently delivers the genetic material, but is 
not optimal for repeated uses. Though electroporation has proven to be successful, we utilized 
the second approach due to the need of repeated exposure to exogenous factors.  
Repeated electroporation can damage the cells and hinder proliferation and expansion, 
thus inhibiting reprogramming. Cationic delivery vehicles are liposome-type molecules that will 
spontaneously interact with the cell surface to introduce genetic material to the cytoplasm. This 
method utilizes the fact that cells cultured in vitro have a net negative charge (Dwarki et al., 
1993). The lipid delivery vehicles contain a positive charge and are naturally attracted to the cell 
surface. Incubation of cationic lipid-delivery vehicles containing genetic information with target 
cells can initiate cellular reprogramming with the uptake of mRNA.  
The method of mRNA introduction can be easily managed, but maintaining sufficient 
volumes of RNA can be problematic. RNA rapidly degrades and is less stable than its DNA 
counterpart.  Messenger RNA can be synthesized and quantified in vitro to obtain an adequate 
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amount for the transfection. This in vitro transcribed messenger RNA is also packaged similar to 
the form found in vivo in the cytoplasm. The addition of a 5’ cap and poly-A tail is utilized in the 
in vitro transcription process to mimic its natural form to be translated.  
Reprogramming and the induction of pluripotency using in vitro transcribed mRNA 
transfection have proven successful in human and murine cell lines (Warren et al., 2010). The 
objective of this study was to deliver ivtRNA to bovine fetal fibroblasts in a manner consistent 
with induced pluripotency. Green fluorescent protein (GFP) ivtRNA was delivered and 
fluorescence was measured by flow cytometry to determine a desirable transfection 
concentration and time course. Cellular viability was examined to address cytotoxicity.  
The stimulation of endogenous bovine OCT gene expression is critical in the cellular 
reprogramming process. OCT4 has been referred to as the “Gatekeeper in the beginnings of 
mammalian development” (Pesce and Schöler, 2001). OCT4, a part of the POU domain, remains 
expressed throughout development, but down-regulation becomes simultaneous with cellular 
differentiation (Jin et al., 2002).  The up-regulation of endogenous OCT4 is necessary to 
jumpstart the reprogramming network, including SOX2 and Nanog. OCT4 transcription factor is 
normally expressed early within embryo development—almost exclusively within the 
blastomeres. As the organism develops, OCT4 expression becomes confined to germ cell 
expression (Pesce and Schöler, 2001). The differentiation process requires activation of specific 
genes and silencing of others. As the developmental process continues, OCT4 expression 
becomes limited in the organism as a whole. The silencing of genes required for pluripotency 
and rapid cell division is mandatory as a cell becomes more specialized. The specialized—or 
differentiated—cell becomes distinct, producing transcripts specific to its cell type. The down-
regulation of embryonic genes becomes necessary for the cell to become specialized.   
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In vitro transcribed mRNA transfection has proven an invaluable tool in understanding 
the mammalian genome due to its ability to deliver exogenous protein without mutagenic effects 
that may be caused by double-stranded DNA. However, a common problem associated with the 
introduction of exogenous mRNA into mammalian cells is the stimulated interferon response. 
Toll-like receptors on the surface of mammalian cells are able to recognize foreign genetic 
patterns and initiate an immune response (Uematsu and Akira, 2007). This response involves a 
change in gene expression to ultimately result in antigen-specific immunity (Takeda and Akira, 
2005). Toll-like receptors have the ability to recognize a vast number of organisms in a very 
specific manor, including viruses, and proceed in step for their elimination (Uematsu and Akira, 
2007). The signaling pathway associated with this invoked immune response is quite elaborate 
and has the ability to become lethal to cells in culture. Experiments within this manuscript 
utilizing ivtRNA lacking modified bases resulted in toxicity to the point of early termination of 
the time course. Previous cellular reprogramming experiments lacking modified bases resulted in 
increased toxicity and a decrease in cellular viability, which lead to the incorporation of modified 
bases (Warren et al., 2010). Essentially, the innate immune response can be avoided with the 
inclusion of modified bases during the in vitro transcription process of in vitro derived mRNA. 
The bases cytidine triphosphate (CTP) and uridine triphosphate (UTP) are replaced with 5-
methylcytidine-5’-triphosphate (5-Methyl-CTP) and pseudouridine-5’-triphosphate (Pseudo-
UTP) during the in vitro transcription process. Cellular reprogramming is achieved via the 
delivery of this modified ivtRNA into the cytoplasm of a cell by a cationic delivery vehicle, 




The process of cellular reprogramming may be enhanced with the inclusion of small 
molecules in the experimental regime. These small molecules have the ability to promote or 
enhance reprogramming by direct involvement in the reprogramming mechanisms themselves. 
The small molecules, or inhibitors, utilized include MEK inhibitor PD0325901, GSK3 inhibitor 
CHIR99021, and G9a histone deacetylase inhibitor NuP0148. The combination of PD0325901 
and CHIR99021 has been shown to promote pluripotency when combined with LIF (Silva et al., 
2008). PD0325901 has been reported to promote growth in iPSCs and possibly inhibit growth in 
non-iPSCs (Shi et al., 2008). Histone deacetylase inhibitors have been shown to enhance cellular 
reprogramming in bovine somatic cells (Staszkiewicz et al., 2013). The combination of these 
inhibitors has the potential to enhance the reprogramming process and possibly lead to the 
replacement of pluripotent transcription factors all together.  
Primay endpoint of this evaluation is to report the induced expression of endogenous 
pluripotency genes. This induction is the first step in cellular reprogramming to pluripotency. 
Stimulation of endogenous pluripotency transcription factors suggests that the epigenetic 
modifications required for altered gene expression have been initiated, and the target cells are on 
the path to becoming ESC-like cells.  
Materials and Methods 
Templates were obtained from Addgene as plasmids containing sequences encoding GFP 
or human OCT4, SOX2, KLF4, c-MYC. Plasmid inserts were excised by restriction enzyme 
prior to in vitro transcription utilizing mMESSAGE mMACHINE Kit (High Yield Capped RNA 
Transcription Kit) according to manufacturer protocol. The reaction was packaged with the Poly 
(A) Tailing Kit (Applied Biosystems AM1350) followed by purification using MEGAclear spin 
columns (Applied Biosystems AM1908). KMOS (Klf4, c-Myc, Oct4, Sox2) stoiciometry of 
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1:1:3:1 cocktail was utilized.  RNA transfections were carried out using Lipofectamine® 
RNAiMAX Reagent. Modified 2X NTP/CAP (5-methylcytidine-5’-triphosphate (5-Methyl-CTP) 
and pseudouridine-5’-triphosphate (Pseudo-UTP)) was substituted for manufacturer supplied 2X 
NTP/CAP during in vitro transcription of modified mRNA. All cells transfected were bovine 
fetal fibroblasts (BFF), passage 2-5, cultured at 37°C and 5% CO2 in specified media.  
Cell Culture 
All target cells were obtained from previously isolated primary cultures (site angelica). 
Primary cultures of fibroblasts were established from eight 50-day-old bovine fetuses recovered 
from a local abattoir according to previous protocol (Giraldo et al., 2009). With the exception of 
the primary culture, the fibroblasts were passaged at 80% confluence. Cultures were passaged by 
releasing cells with trypsin (0.25%), counted using a hemacytometer and re-seeded at an initial 
concentration of 100,000 cells/flask. These bovine fetal fibroblasts (BFFs) were expanded prior 
to treatment in each experiment. 
Cell Cryopreservation 
Fibroblast cells were frozen and thawed as needed. For cell freezing, the fibroblasts were 
resuspendend in DMEM supplemented with 10% BCS and 10% dimethyl sulfoxide (DMSO) and 
cooled at 1.0°C/min until reaching -80°C before storage in liquid nitrogen. Approximately 
1,000,000 cells were frozen in 1 ml of freezing medium per cryovial. Cells were thawed by 
holding the cryovial for 10 sec at room temperature followed by submersion in 38°C water. 
Thawed cells were washed once in culture medium before being replated. 
RNA Transfection 
Lipofectamine® RNAiMax Reagent mediated transfection was carried out within 
suggested concentration ranges. Manufacturer protocol suggests 0.5-1.5 μl of Lipofectamine 
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reagent per well of 24-well plate leading to the utilization of 1.0 μl Lipofectamine reagent per 
well. The protocol suggests 6 pmol of RNA per well of 24-well plate, but various concentrations 
were evaluated (1 pmol, 2 pmol, and 4 pmol) according to previous study suggestions (Warren et 
al., 2010). RNA 100 ng/µL was diluted per manufacturer instructions and componentes were 
pooled and incubated 15 minutes at room temperature prior to being dispensed to culture media.  
All cells transfected were bovine fetal fibroblasts, passage 2-5, cultured at 37°C and 5% CO2 in 
specified media.  
Flow Cytometry 
Single cell suspension in PBS without calcium and magnesium in a range of 
concentrations (50,000-800,000 cells/mL) were evaluated with SPECIFIC MACHINE. The 
relative fluorescence was used as (actual number used from software) for comparison. Mean 
intensity? 
Cellular Viability 
Cellular viability was measured by counting a final number of cells per well following 
seeding of constant number of cells for all wells. Cells were counted using a hemocytometer and 
phase contrast microscope. The numbers represented the total number of cells within each well at 
the time of measurement.  
Gene Expression 
Cells were extracted from each well followed by mRNA isolation using Dynabeads® 
mRNA DIRECT™ Kit. Each sample mRNA was eluted in 15 ul RNase-free water and placed 
directly into Bio-Rad iScript™ cDNA Synthesis Kit reaction. The iScript™ kit utilized reverse 
transcriptase to transform mRNA into a more stable form, cDNA. The cDNA transcribed from 





Basic PCR reactions consisted of 25 ul Jumpstart Red Mix, 2 ul forward primer, 2 ul 
reverse primer, 10 ul cDNA, and 11 ul dH20 for a total of 50 ul. PCR was performed with a 
Hotstart of 94°C (2 min), denature 94°C (30 sec), annealing 60°C (30 sec), extension 72°C (1 
min) for 30 cycles followed by a final extension at 72°C (5 min). The final PCR products were 
evaluated by gel electrophoresis using 1% agarose gel containing ethidium bromide. The gel was 
observed under UV light using BIO-RAD Universal Hood II and density gradient was evaluated 
with Quanity One Analysis Software.  
Q-PCR procedure utilized EvaGreen® based method. Bio-Rad SsoFast™ EvaGreen® 
Supermix was used with primers from Table A.1. Q-PCR was performed with an enzyme 
activation at 95°C (1 min) followed by 40 repeats of denature at 95°C (5 sec) and annealing at 
60°C (30 sec). A final denature and extension step was performed at 95°C (1 min) and 55°C (1 
min) respectively. A melt-curve analysis was carried out by repeating 80 times and increasing 
5°C every 10 seconds beginning at 55°C.   
Statistical Analysis 
Data were analyzed for all preliminary GFP experiments using SAS statistical software, 
GLM ANOVA, Levene’s Test for homogeneity of variance. Tests for normality, Shapiro-Wilks, 
performed and no transformations were made. Cell viability of modified transfection 
experiments were evaluated using an ANOVA under normal assumptions. Relative gene 
expression was evaluated with REST statistical software. The program uses the geometric mean 
of multiple reference genes to normalize the results against genes of interest (GOI) since ratios 
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are used for data evaluation; this is called the Normalization Factor. Individual expressions are 
calculated relative to each reference gene and averaged using the geometric mean.   
 Expression = GOI concentration / GEOMEAN (refConc1, refConc2) 
Estimates of concentrations vary exponentially due to the equation form of c = A x eCT.  
Experimental Design 
Experiment 1 
The 24-well plate was prepared with five treatment groups arranged in columns 
containing four wells each; Control, No RNA, Low, Medium, High. The “Control” group 
contains 5x104 bovine fetal fibroblasts grown in normal growth medium; “No RNA” contains 
bovine fetal fibroblasts treated with Lipofectamine lacking ivtRNA. The remaining three 
treatment groups contained bovine fetal fibroblasts transfected with three separate concentrations 
of ivtRNA-Lipofectamine complex and were cultured in normal growth medium (Dulbecco’s 
Modified Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS), 1% Penicillin/Streptomycin 
(P/S)). All wells were seeded at a density of 5x104 of bovine fetal fibroblasts BEZ2 passage 2 
(P2). Treatment groups were transfected with specific concentrations of ivtRNA encoding GFP 
utilizing lipofectamine as the transfection reagent. GFP relative expression was measured by 
flow cytometry 24-hours post-transfection. The measurement of cellular viability was 
investigated by determining the number of surviving cells following the transfection of a 
constant number of cells in each well. 
Experiment 2 
A 24-well plate was seeded with BFF P4 bovine fetal fibroblasts at the same density with 
normal growth medium. The treatment groups were in columns containing four wells each. The 
first column was the control group containing target cells grown under normal conditions. All 
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other columns were transfected with 2pmol of GFP ivtRNA per well. The second column was 
evaluated at 12 hours post-transfection and remaining columns were evaluated in 12-hour 
increments. The treatment groups were as follows: Control, 12-Hour, 24-Hour, 36-Hour, 48-
Hour, and 60-Hour. The control group was evaluated simultaneously with the 60-Hour treatment 
group. Cellular viability was evaluated by counting cells after seeding a constant number of cells 
in each well.  
Experiment 3 
A 24-well plate was seeded with BFF P6 at 5x104 cells per well. The GFP ivtRNA was 
used to transfect the target cells over an extended period. The plate was divided into columns 
containing four wells each as treatment groups Control, 3-day, 6-day, 9-day, 12-day and 15-day. 
All treatment groups other than the control were transfected with 2pmol per well of GFP ivtRNA 
every other day. Cells were evaluated for mean fluorescence using flow cytometry and cellular 
viability was assessed by cell counting.  
Experiment 4 
In vitro transcribed OCT4 mRNA was delivered to bovine fetal fibroblasts BFF P5, 
followed by examination for endogenous expression. Previous concentration transfection 
conditions were used to transfect the cells every other day for 12 days with known pluripotency 
factor OCT4. Endogenous bOCT4 gene expression was measured by total RNA extraction and 
reverse transcription to cDNA, followed by PCR utilizing bovine OCT4 primers and bovine 
PolyA primers as a control. 
Experiment 5 
Bovine fetal fibroblasts BFF P1 were seeded at a density of 2.5x104 cells per well. 
Treatment groups were transfected with modified ivtRNA encoding green fluorescent protein 
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(GFP) to evaluate the effects on cellular viability and fluorescence. The cellular viability was 
measured by counting a final number of cells after seeding a constant number of cells in all 
treatment groups. The control group consisted of bovine fetal fibroblasts cultured in normal 
growth medium (DMEM, 10%FBS, 1% P/S). A no RNA (NR) group was held under the same 
conditions with the addition of the transfection reagent, Lipofectamine, to account for toxicity 
due to the transfection reagent alone. The cells were transfected every other day for 12 days and 
were evaluated on days 3, 6, 9 and 12 for viability and fluorescence by flow cytometry.  
Experiment 6 
This experiment consisted of bovine fetal fibroblasts BFF transfected with modified 
ivtRNA cocktails encoding multiple pluripotency factors; 3Factor (KOS) or 4Factor (KMOS) 
combinations. The controls were identical to the previous experiments, but treatment groups 
were transfected with modified in vitro-transcribed mRNA encoding either three factors (3F: 
OCT4, SOX2, KLF4) or four factors (4F: OCT4, SOX2, KLF4, c-MYC). Transfections were 
performed every other day for 24 days with      media changed every day. Cells were evaluated 
for toxicity by cell counting at the end of the experiment. 
Experiment 7 
Reprogramming experiments were carried out to evaluate possible change in gene 
expression of bovine fetal fibroblasts. The target cells, BFF, were seeded at a density of 1x104 
cells per well containing irradiated mouse embryonic fibroblast (iMEF) feeder layers. Cells were 
transfected every day with KMOS cocktail containing modified ivtRNA with media changed 
daily. Cells were transfected daily for 21 days and cultured in either +/-3i media (+3i contains 
three inhibitors PD0325901, CHIR99021, NuP0148 and -3i lacks inhibitors). Pictures were taken 
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of all wells on Days 15 and 21. The cells were harvested, counted, and total RNA was recovered 
on Day 21. Gene expression was evaluated with quantitative PCR.  
Results 
Experiment 1: GFP ivtRNA Concentration Evaluation 
Bovine fetal fibroblast cells transfected with 2 pmol (medium mRNA concentration) 
displayed the highest relative fluorescence with p<0.001 (graph 3.1). The cellular viability 
proved to be variable in this particular evaluation, which can be expected with this type of 
treatment (graph 3.2).  
An optimum ivtRNA concentration was established by selecting the concentration that 
yeilded the highest relative fluorescence. The optimum concentration of GFP ivtRNA (2 pmol 
per well) was used to transfect cells, and GFP expression was measured every 12 hours post 
transfection to determine an expression time course from a single transfection. The relative 
fluorescence peaked between 24 and 36 hours post transfection (fig. 3.3). Cell viability decreased 
when compared to the control, with transfected treatments having significantly fewer cells than 
controls at all time points (fig. 3.4). Cell viability was measured by counting the final number of 
cells in each well after seeding a constant number of cells.  A notable observation was the 
decrease in cellular viability once the Lipofectamine containing the GFP mRNA was added to 
the cell culture, when compared to the control group. Each treatment group receiving ivtRNA 






Figure 3.1 GFP ivtRNA Concentration Fluorescence 
 
 






Experiment 2: GFP ivtRNA Time Course Evaluation 
Once an optimal concentration of mRNA for transfection was established, the time 
course for delivery was addressed. GFP expression was measured every 12 hours post-
transfection by the mean fluorescence reading given by flow cytometry. Gene expression peaked 
between 24 and 36 hours and slowly declined until the final measurement of 60 hours (Fig. 3.3). 
The final measurement was not significantly different from the first 12-hour measurement. No 
significant difference was observed between the measurements taken at 24 and 36 hours, but 
these measurements were significantly different from the rest. 
 
 








Figure 3.4 GFP ivtRNA Expression Time Course Cellular Viability 
 
Experiment 3: GFP ivtRNA Extended Time Course Evaluation 
Cells were transfected every other day with GFP ivtRNA, and expression was determined 
by flow cytometry on days 3, 6, and 9. The GFP was examined every 3 days with flow 
cytometry, but cells were no longer viable by day 12.  Repeated transfections measured every 
three days illustrated greater fluorescence within treatment groups when compared to controls, 
but did not increase fluorescence with repeated transfections (fig. 3.5). Cell count of all treatment 
groups illustrates a decrease in cellular viability of ivtRNA treated groups when compared to 
both controls (fig. 3.6). No difference was observed in viability of all cells treated with ivtRNA 
encoding GFP when compared to controls (p=0.9). A significant difference was observed in 
fluorescence on all time points when compared to controls (day3 p=0.004, day6 p=0.004, day9 




Figure 3.5 GFP ivtRNA Expression Extended Time Course 
 
 







Experiment 4: OCT4 ivtRNA Transfection and Endogenous Activation 
A PCR gradient was used to determine an optimal annealing temperature for the bovine 
OCT4 primers where no binding to the human OCT4 sequence could occur. As the annealing 
temperature increased, the affinity for the human oct4 plasmid decreased (fig. 4.1). The optimal 
temperature where the primers bind to the bovine sequence ONLY was then used in subsequent 
PCR reactions to determine the presence of endogenous OCT4. As the annealing temperature 
increases, the affinity for the human oct4 plasmid decreases. The maximum temperature for the 
primers to anneal to the bovine oct4 plasmid—and not to the human oct4 plasmid—is between 
58.9 and 63.3 degrees Celsius.  
Bovine fetal fibroblasts were transfected with ivtRNA encoding human Oct4 every other 
day. RNA was isolated on day 12 and analyzed by semi-quantitative RT-PCR for expression of 
the endogenous OCT4. Expression was quantitated by comparing intensities of electrophoresis 
bands using poly-adenylate polymerase (PAP) gene for standardization. Expression levels were 
expressed as the ratio of intensities of electrophoresis bands. The low concentration of hOCT4 
mRNA transfection in the bovine fibroblast cells up-regulated endogenous bOCT4 mRNA 
expression measured qualitatively by comparing the intensity per mm2 of the bands present on 
the gel (fig.4.2). The ratio of bOCT4 to bPolyA was inverted when compared to the two control 
groups (fig.4.2) indicating up-regulation. The ratio (OCT4/PAP) was 0.7 for untreated controls, 
0.68 for cells transfected without RNA, and 1.2 for cells transfected with 140 ng per well 
ivtRNA encoding hOCT4. Expression was not detected in higher concentration treatments due to 
lack of cell survival. PCR conditions previously optimized did not amplify the human OCT4 
mRNA, thus detecting the presence of endogenous OCT4. The increased ratio of 1.2 suggests the 
stimulation of endogenous OCT4 expression. This can be seen by the inverse of the band 
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intensity seen in U5 and U6 when compared to the band intensity ratio of U1&U2 and U3&U4. 
There is an inverse in the concentration ratio of the treated group.   
 
Table 3.1 Optimal PCR Conditions for Binding Bovine OCT4 Sequence 






65.0 + - - 
63.3 ++ - - 
58.9 +++ - - 
55.8 +++ + - 
 
  






         B   H   C    B   H  C    B   H  C   B   H   C 
          65.0°C        63.3°C        58.9°C        55.8°C 
Figure Legend 3.7 
B:  Bovine OCT4 plasmid  
H:  Human OCT4 plasmid 
C:  Control, no plasmid 




Figure Legend 4.2  
U1—Control Bovine OCT4 
U2—Control Poly-Adenylate Polymerase 
U3—No RNA Bovine OCT4 
U4—No RNA Poly-Adenylate Polymerase 
U5—Low Bovine OCT4 
U6—Low Poly-Adenylate Polymerase 
 
 







Table 3.2 Expression Comparison to Housekeeping Gene 
Sample Primers Mean Value INT INT Ratio  
Control bOCT4 166.64 0.7 
Control PAP 237.92 
No RNA bOCT4 157.76 0.68 
No RNA PAP 233.13 
Low bOCT4 216.27 1.2 
Low PAP 182.18 
 
Experiment 5: Modified GFP ivtRNA Transfection Evaluation 
The introduction of synthetic mRNA containing modified bases maintains cellular 
viability when compared to controls. No difference in viability of all cells treated with synthetic 
mRNA encoding GFP was observed when compared to controls (p=0.9). There was a significant 
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difference in fluorescence on all time points when compared to controls (day3 p=0.004, day6 
p=0.004, day9 p=0.007, day12 p=0.04). 
 
Figure 3.9 Relative Fluorescence of Modified GFP ivtRNA Transfection 
 
 



































































Modified 3/4Factor ivtRNA Cell Viability
Experiment 6: Three Factor and Four Factor Modified ivtRNA Time Course Evaluation 
The experiment consisted of bovine fetal fibroblasts transfected with modified synthetic 
mRNA encoding pluripotency factors. The controls were identical to the previous experiment, 
but treatment groups were transfected with modified synthetic mRNA encoding either three 
factors (3F-KOS: OCT4, SOX2, KLF4) or four factors (4F-KMOS: OCT4, SOX2, KLF4, c-
MYC). The treated cells were transfected every other day and evaluated on day 24 for cellular 
viability. No difference was observed in cellular viability in all treatment groups when compared 
to controls (p=0.2) (fig. 5.1). The introduction of synthetic mRNA containing modified bases 

















Figure 3.11 Measurement of Cellular Viability Post Modified 4F/3F ivtRNA Transfection 
 
Experiment 7: Modified Four Factor Transfection With and Without Inhibitors 
Expression of Oct4 was up-regulated in both treatment groups when compared to 
controls. The Ct values were evaluated by REST© Software (Pfaffl et al., 2002). The hypothesis 
test performed in this program determines whether there is a significant difference between 
controls and treatment groups while taking into account reaction efficiency and normalization of 
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multiple reference genes. The expression values obtained are a result of the gene of interest 
concentration divided by the reference gene concentration. The transfected group lacking 
inhibitors (-3i) had a significant increase in Oct4 expression with a value of 334.055 (p=0.007) 
when compared to controls. Nanog was not different than controls with expression value of 3.88 
(p=0.136). The transfected group including inhibitors (+3i) had a significant increase in Oct4 
expression with a value of 55.827 (p=0.004) when compared to controls. Nanog was 
significantly down-regulated with an expression value of 0.077 (p=0.020) when compared to 
controls. All values where normalized against both PAP and GAPDH, each having a reaction 
efficiency near 100%.  
 
 

















Modified 4Factor +/- 3i Cell Viability
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Figure 3.13 Relative Expression of Oct4 and Nanog normalized against housekeeping genes PAP and GAP
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Figure 3.14: BFF cells 15 days culture and daily transfections: (A) 4F -3i Day 15, (B) 4F +3i Day 15, (C) Control Day 
15, photos obtained from EVO phase contrast microscope 
 
C A B 
A B C 
Figure 3.15: BFF cells 21 days culture and daily transfections: (A) -3i Day 21, (B) +3i Day 21, (C) Control Day 21, photos 





The addition of exogenous in vitro-transcribed messenger RNA can be successful in 
influencing relative gene expression within bovine fetal fibroblasts. These mammalian cells were 
capable of incorporating foreign transcripts encoding green fluorescent protein into their normal 
cellular processes, which resulted in expression. Relative gene expression was influenced on a 
cellular level, indicating the cells ability to be reprogrammed with the addition of exogenous 
transcripts. 
The increased levels of toxicity and the decrease in cellular viability were possibly due to the 
invoked interferon response that is normally initiated when confronted with viral infection.  
During cellular reprogramming, exogenous transcription factors are introduced to the 
cells of interest to stimulate the production of endogenous transcripts. The presence of 
endogenous expression is often difficult to determine, and specific measures are carried out to 
distinguish endogenous from exogenous transcripts. If no endogenous stimulation occurs, the 
cessation of exogenous transcripts will cause the cell to return to normal gene expression. If, in 
fact, endogenous expression is stimulated and exogenous transcripts are halted, the cell should 
continue to translate the endogenous sequence.  The stimulation of endogenous expression could 
be the first steps in complete reprogramming regimes. 
Transfection of bovine fibroblast cells with the low concentration of hOCT4 mRNA, up-
regulated endogenous bOCT4 mRNA expression. It was measured qualitatively by comparing 
the intensity per mm2 of the bands present on the agarose gel. Repeated transfections with 
ivtRNA resulted in toxicity unrelated to the transfection agent. The increased toxicity was 
thought to be in response to the addition of exogenous material invoking an innate immune 
response. Cellular viability decreased with introduction of ivtRNA. The control group, NR, 
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introduced to the transfection reagent alone did not experience the levels of toxicity of those 
treatment groups receiving in vitro transcribed messenger RNA. This addition of exogenous 
material mirrors that of viral replication processes, and the toxicity is a natural cellular response. 
Experiments utilizing ivtRNA including modified bases reduced cell toxicity of ivtRNA. These 
modified bases aid in the decrease of the immune response from the target cells and may 
improve the reprogramming process. The cells will maintain their viability and thus survive the 
treatment regime. The expected viability concern was eliminated by incorporating these modified 
bases. The modified bases decrease the interferon response normally stimulated with the 
introduction of exogenous messenger RNA. Further experiments were implemented with 
modified ivtRNA encoding pluripotency factors OCT4, SOX2, KLF4 and c-MYC during the 





















SUMMARY AND CONCLUSIONS 
 
Numerous epigenetic barriers must be overcome during the process of cellular 
reprogramming. These barriers have the ability to impede the stimulated up-regulation of 
embryonic transcription factors within somatic cells. The complete induction of pluripotency is 
the ability to overcome a plethora of epigenetic modifications. These barriers are more difficult 
to be carried out than a simple cell lineage switch. There are cells that can be transformed from 
one cell type to another, such as B cells into macrophages, with the stimulation from a single 
stimulus with 100% efficiency within a 48-hour time period (Xie et al., 2004). This level of 
efficiency does not occur within the induction of pluripotency. Mouse fibroblasts were 
reprogrammed 18 days after transduction (Li et al., 2011), human ESC derived fibroblasts 
displayed tight morphology and distinct colony borders by the end of the second week of 
transfection (Warren et al., 2010), and germinal vesicle extract treated cells (GV-ETC) exhibited 
colony formation in 7 days (Miyamoto et al., 2009). There are numerous methods and 
combinations of stimuli that have improved efficiency, but none have come close to the 
previously mentioned 48-hour conversion. A complete understanding of the primary mechanisms 
to overcome allows improvement in the reprogramming efficiency.  
Transfection with ivtRNA into bovine fetal fibroblasts was not well defined which 
required preliminary experiments to be performed. These fundamental experiments outlined the 
parameters for transfection. Transcripts encoding GFP were obtained as a template from 
Addgene plasmid 26822 containing the sequence for eGFP, or Enhanced Green Fluorescent 
Protein. A concentration of ivtRNA for transfection needed to be established. Lipofectamine® 
RNAiMAX Reagent protocol suggests 6 pmol RNA per well 24-well plate, as well as a range of 
0.6-30 pmol per well. A previous experiment supplied 1200 ng (1.71 pmol) per well in a 6-well 
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plate (Warren et al., 2010).  A range of concentrations was developed from the suggested 
concentrations to establish uniformity of low (1 pmol), medium (2 pmol), and high (4 pmol) 
concentrations per well. When scaled down from 6-well format to 24-well format, the final 
amount of ivtRNA supplied to each well was low (140 ng), medium (280 ng), and high (560 ng). 
The preliminary GFP ivtRNA transfection supported the medium 2 pmol per well concentration 
as the optimal concentration which compares to the 1.71 pmol concentration previously 
mentioned. However, the endogenous expression of Oct4 in the “unmodified” experiment was 
up-regulated within the low concentration group of 1 pmol per well. It is thought this was due to 
the increased toxicity of increased concentrations of unmodified ivtRNA which was seen in 
previous experiments (Warren et al., 2010).  
Once the optimal concentration of 2 pmol ivtRNA per well was established, a time course 
for transfections was evaluated. The GFP ivtRNA time course evaluation experiment displayed 
peak GFP relative expression between 24 and 36 hours, leading to the decision to transfect every 
other day instead of everyday (Warren et al., 2010). The time course was utilized throughout 
most experiments, though possibly under an incorrect assumption. The Addgene plasmid 26822 
encodes for eGFP, or “enhanced” GFP, which is a recombinant form utilized for its extended 
fluorescence and increased stability (Cormack et al., 1996). The peak time of GFP relative 
expression measured may be due to an extended ivtRNA half-life when compared to Oct4 
ivtRNA half-life. The delay in transfection time when using pluripotency transcription factors 
may not have been advantageous. The benefit of daily transfections was not evaluated until the 
final experiment, and could possibly have been the source of limited results of reprogramming. 
However, the increase or maintained cellular viability post-transfection with modified ivtRNA 
was greater than previously reported (Warren et al., 2010). There was no difference between 
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transfected cells and control cells or cells treated with the transfection reagent alone. Cellular 
viability maintenance may be attributed to the less rigorous transfection regime. 
One of the first embryonic transcription factors that must be stimulated is pluripotency 
factor OCT4 (Kim et al., 2009b). The decrease in OCT4 expression leads to differentiation and 
cell specification; therefore, its stimulation is required for the intricate pluripotency network to 
become active (Pesce and Schöler, 2001). The delivery of Oct4 alone induced pluripotency in 
adult neural stem cells (Kim et al., 2009b). The abundance of expression in early embryonic 
development has long been silenced in a somatic cell line. Methylation of the Oct4 promoter is 
the key to managing gene expression. The promoter is highly methylated in somatic cells due to 
pluripotency silencing, and completely unmethylated in embryonic cells (Gidekel and Bergman, 
2002; Simonsson and Gurdon, 2004). The barriers that are overcome to stimulate this gatekeeper 
of pluripotency are necessary for the induction of other embryonic stem cell transcription factors. 
Endogenous Oct4 expression was indeed stimulated, indicating the initiation of the 
reprogramming process within these bovine fetal fibroblasts. The epigenetic modifications 
required for the induction of pluripotency were in fact engaged. Cell morphology was likewise 
affected during the process. The cells began to change and form tightly bound groups of cells—
many with distinct borders.  
The reprogramming regime including inhibitors (+3i) during culture did not differ from 
transfected culture lacking inhibitors (-3i) in terms of up-regulation of embryonic transcription 
factor Oct4. The near 100-fold increase in endogenous Oct4 expression is consistent with mouse 
fibroblasts reprogrammed to iPSCs compared to mouse ESCs (Zhou and Zeng, 2013). Nanog, 
however, was down-regulated in the +3i treatment group.  In a previous study, the inclusion of 
MEK inhibitor, PD0325901, and GSK3 inhibitor, CHIR99021—in combination during the 
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reprogramming of cells that have been recently infected, have had a negative effect on the 
required gene expression (Feng et al., 2009). The timing of culture introduction to these 
inhibitors may play a role in whether or not the reprogramming is enhanced or inhibited. The 
epigenetic remodeling the cells are undergoing must be at an optimal time point for enhancement 
to take place. Inhibitor concentration is also a contributing factor for efficient and successful 
reprogramming. The concentrations of CHIR99021 and PD0325901 utilized were consistent 
with previous studies (Yu et al., 2011) and NuP0148 concentration was estimated due to its 
recent development and current concentration evaluation experiments currently being carried out 
by NuPotential, LLC. The alteration of this final concentration or combination of concentrations 
may still need to be evaluated in future experiments.  
The stimulation of endogenous OCT4 expression is encouraging to the reprogramming 
process. Somatic cells with the ability to become reprogrammed to be ESC-like cells have the 
ability to aid in therapeutic applications and other research endeavors. If these cells are in fact 
reprogrammed to a less differentiated state, they might also provide a more efficient nuclear 
donor for somatic cell nuclear transfer. This less-differentiated cell would require less epigenetic 
modifications by the recipient oocyte. The overall success of SCNT would then increase yielding 
positive results for embryos to transfer. An increase in SCNT efficiency would be advantageous 









Adachi, K., H. Suemori, N. Nakatsuji, and E. Kawase. 2011. The Role of SOX2 in Maintaining 
Pluripotency and Differentiation of Human Embryonic Stem Cells. 
Audouy, S. L., L. M. H. de Leij, D. Hoekstra, and G. Molema. 2002. In Vivo Characteristics of 
Cationic Liposomes as Delivery Vectors for Gene Therapy. Pharm Res 19: 1599-1605. 
Avilion, A. A., S. K. Nicolis, L. H. Pevny, L. Perez, N. Vivian, and R. Lovell-Badge. 2003. 
Multipotent cell lineages in early mouse development depend on SOX2 function. Genes 
& Development 17: 126-140. 
Babaie, Y., R. Herwig, B. Greber, T. C. Brink, W. Wruck, D. Groth, H. Lehrach, T. Burdon, and 
J. Adjaye. 2007. Analysis of Oct4-Dependent Transcriptional Networks Regulating Self-
Renewal and Pluripotency in Human Embryonic Stem Cells. STEM CELLS 25: 500-510. 
Briggs, R., and T. J. King. 1953. Factors affecting the transplantability of nuclei of frog 
embryonic cells. Journal of Experimental Zoology 122: 485-505. 
Briggs, R., and T. J. King. 1957. Changes in the nuclei of differentiating endoderm cells as 
revealed by nuclear transplantation. Journal of Morphology 100: 269-311. 
Briggs, R., and T. J. King. 1960. Nuclear transplantation studies on the early gastrula (Rana 
pipiens): I. Nuclei of presumptive endoderm. Developmental biology 2: 252-270. 
Campbell, K. H. S., J. McWhir, W. A. Ritchie, and I. Wilmut. 1996. Sheep cloned by nuclear 
transfer from a cultured cell line. Nature 380: 64-66. 
Chickarmane, V., C. Troein, U. A. Nuber, H. M. Sauro, and C. Peterson. 2006. Transcriptional 
Dynamics of the Embryonic Stem Cell Switch. PLoS Comput Biol 2: e123. 
Cho, H.-J., C.-S. Lee, Y.-W. Kwon, J. S. Paek, S.-H. Lee, J. Hur, E. J. Lee, T.-Y. Roh, I.-S. Chu, 
S.-H. Leem, Y. Kim, H.-J. Kang, Y.-B. Park, and H.-S. Kim. 2010. Induction of 
pluripotent stem cells from adult somatic cells by protein-based reprogramming without 
genetic manipulation. Blood 116: 386-395. 
Cormack, B. P., R. H. Valdivia, and S. Falkow. 1996. FACS-optimized mutants of the green 
fluorescent protein (GFP). Gene 173: 33-38. 
Dang, D. T., K. E. Bachman, C. S. Mahatan, L. H. Dang, F. M. Giardiello, and V. W. Yang. 
2000. Decreased expression of the gut-enriched Krüppel-like factor gene in intestinal 
adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial 
adenomatous polyposis patients. FEBS Letters 476: 203-207. 
Duinsbergen, D., M. Eriksson, P. A. C. t Hoen, J. Frisén, and H. Mikkers. 2008. Induced 




Dwarki, V. J., R. W. Malone, and I. M. Verma. 1993. [43] Cationic liposome-mediated RNA 
transfection. In: W. Ray (ed.) Methods in Enzymology No. Volume 217. p 644-654. 
Academic Press. 
Eminli, S., J. Utikal, K. Arnold, R. Jaenisch, and K. Hochedlinger. Reprogramming of Neural 
Progenitor Cells into Induced Pluripotent Stem Cells in the Absence of Exogenous Sox2 
Expression. 
Esteban, M. A., J. Xu, J. Yang, M. Peng, D. Qin, W. Li, Z. Jiang, J. Chen, K. Deng, M. Zhong, J. 
Cai, L. Lai, and D. Pei. 2009. Generation of Induced Pluripotent Stem Cell Lines from 
Tibetan Miniature Pig. Journal of Biological Chemistry 284: 17634-17640. 
Evans, M. J., and M. H. Kaufman. 1981. Establishment in culture of pluripotential cells from 
mouse embryos. Nature 292: 154-156. 
Evans, P. M., W. Zhang, X. Chen, J. Yang, K. K. Bhakat, and C. Liu. 2007. Krüppel-like Factor 
4 Is Acetylated by p300 and Regulates Gene Transcription via Modulation of Histone 
Acetylation. Journal of Biological Chemistry 282: 33994-34002. 
Ezashi, T., B. P. Telugu, A. P. Alexenko, S. Sachdev, S. Sinha, and R. M. Roberts. 2009. 
Derivation of induced pluripotent stem cells from pig somatic cells. Proc Natl Acad Sci U 
S A 106: 10993-10998. 
Feng, B., J.-H. Ng, J.-C. D. Heng, and H.-H. Ng. 2009. Molecules that Promote or Enhance 
Reprogramming of Somatic Cells to Induced Pluripotent Stem Cells. Cell stem cell 4: 
301-312. 
Foster, K. W., A. R. Frost, P. McKie-Bell, C.-Y. Lin, J. A. Engler, W. E. Grizzle, and J. M. 
Ruppert. 2000. Increase of GKLF Messenger RNA and Protein Expression during 
Progression of Breast Cancer. Cancer Research 60: 6488-6495. 
Fusaki, N., H. Ban, A. Nishiyama, K. Saeki, and M. Hasegawa. 2009. Efficient induction of 
transgene-free human pluripotent stem cells using a vector based on Sendai virus, an 
RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol 
Sci 85: 348-362. 
Gidekel, S., and Y. Bergman. 2002. A Unique Developmental Pattern of Oct-3/4DNA 
Methylation Is Controlled by a cis-demodification Element. Journal of Biological 
Chemistry 277: 34521-34530. 
Gilbert, S. F. 2010. Developmental Biology. Ninth Edition ed. Sinauer Associates, Inc., 
Sunderland, Massachusetts, USA. 
Giraldo, A. M., J. W. Lynn, M. N. Purpera, T. D. Vaught, D. L. Ayares, R. A. Godke, and K. R. 
Bondioli. 2009. Inhibition of DNA methyltransferase 1 expression in bovine fibroblast 
cells used for nuclear transfer. Reproduction, Fertility and Development 21: 785-795. 
52 
 
González, F., S. Boué, and J. C. I. Belmonte. 2011. Methods for making induced pluripotent 
stem cells: reprogramming à la carte. Nature Reviews Genetics 12: 231-242. 
Gurdon, J. B. 1962a. Adult frogs derived from the nuclei of single somatic cells. Developmental 
biology 4: 256-273. 
Gurdon, J. B. 1962b. The transplantation of nuclei between two species of Xenopus. 
Developmental biology 5: 68-83. 
Gurdon, J. B., T. R. Elsdale, and M. Fischberg. 1958. Sexually Mature Individuals of Xenopus 
laevis from the Transplantation of Single Somatic Nuclei. Nature 182: 64-65. 
Gurdon, J. B., and I. Wilmut. 2011. Nuclear Transfer to Eggs and Oocytes. Cold Spring Harbor 
Perspectives in Biology 3. 
Han, X., J. Han, F. Ding, S. Cao, S. S. Lim, Y. Dai, R. Zhang, Y. Zhang, B. Lim, and N. Li. 
2011. Generation of induced pluripotent stem cells from bovine embryonic fibroblast 
cells. Cell Res 21: 1509-1512. 
Hay, D. C., L. Sutherland, J. Clark, and T. Burdon. 2004. Oct-4 Knockdown Induces Similar 
Patterns of Endoderm and Trophoblast Differentiation Markers in Human and Mouse 
Embryonic Stem Cells. STEM CELLS 22: 225-235. 
Hipp, J., and A. Atala. 2008. Sources of Stem Cells for Regenerative Medicine. Stem Cell 
Reviews and Reports 4: 3-11. 
Hockemeyer, D., H. Wang, S. Kiani, C. S. Lai, Q. Gao, J. P. Cassady, G. J. Cost, L. Zhang, Y. 
Santiago, J. C. Miller, B. Zeitler, J. M. Cherone, X. Meng, S. J. Hinkley, E. J. Rebar, P. 
D. Gregory, F. D. Urnov, and R. Jaenisch. 2011. Genetic engineering of human 
pluripotent cells using TALE nucleases. Nat Biotechnol 29: 731-734. 
Honda, A., M. Hirose, M. Hatori, S. Matoba, H. Miyoshi, K. Inoue, and A. Ogura. 2010. 
Generation of Induced Pluripotent Stem Cells in Rabbits: POTENTIAL 
EXPERIMENTAL MODELS FOR HUMAN REGENERATIVE MEDICINE. Journal of 
Biological Chemistry 285: 31362-31369. 
Hou, P., Y. Li, X. Zhang, C. Liu, J. Guan, H. Li, T. Zhao, J. Ye, W. Yang, K. Liu, J. Ge, J. Xu, 
Q. Zhang, Y. Zhao, and H. Deng. 2013. Pluripotent Stem Cells Induced from Mouse 
Somatic Cells by Small-Molecule Compounds. Science 341: 651-654. 
Jeong Beom, K., H. Zaehres, W. Guangming, L. Gentile, K. Ko, V. Sebastiano, M. J. Araúzo-
Bravo, D. Ruau, H. Dong Wook, M. Zenke, and H. R. Schöler. 2008. Pluripotent stem 
cells induced from adult neural stem cells by reprogramming with two factors. Nature 
454: 646-650. 
Jin, G. P., Z. Y. Chang, H. R. Scholer, and D. Pei. 2002. Stem cell pluripotency and transcription 
factor Oct4. Cell Res 12: 321-329. 
53 
 
Kelberman, D., K. Rizzoti, A. Avilion, M. Bitner-Glindzicz, S. Cianfarani, J. Collins, W. K. 
Chong, J. M. W. Kirk, J. C. Achermann, R. Ross, D. Carmignac, R. Lovell-Badge, I. C. 
A. F. Robinson, and M. T. Dattani. 2006. Mutations within Sox2/SOX2 are associated 
with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. The 
Journal of Clinical Investigation 116: 2442-2455. 
Kim, D., C. Kim, J. Moon, Y. Chung, M. Chang, B. Han, S. Ko, E. Yang, K. Cha, R. Lanza, and 
K. Kim. 2009a. Generation of human induced pluripotent stem cells by direct delivery of 
reprogramming proteins. Cell stem cell 4: 472 - 476. 
Kim, J. B., V. Sebastiano, G. Wu, M. J. Araúzo-Bravo, P. Sasse, L. Gentile, K. Ko, D. Ruau, M. 
Ehrich, D. van den Boom, J. Meyer, K. Hübner, C. Bernemann, C. Ortmeier, M. Zenke, 
B. K. Fleischmann, H. Zaehres, and H. R. Schöler. 2009b. Oct4-Induced Pluripotency in 
Adult Neural Stem Cells. Cell 136: 411-419. 
Kopp, J. L., B. D. Ormsbee, M. Desler, and A. Rizzino. 2008. Small Increases in the Level of 
Sox2 Trigger the Differentiation of Mouse Embryonic Stem Cells. STEM CELLS 26: 
903-911. 
Li, Y., Q. Zhang, X. Yin, W. Yang, Y. Du, P. Hou, J. Ge, C. Liu, W. Zhang, X. Zhang, Y. Wu, 
H. Li, K. Liu, C. Wu, Z. Song, Y. Zhao, Y. Shi, and H. Deng. 2011. Generation of iPSCs 
from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res 21: 196-
204. 
Liao, J., C. Cui, S. Chen, J. Ren, J. Chen, Y. Gao, H. Li, N. Jia, L. Cheng, and H. Xiao. 2009. 
Generation of induced pluripotent stem cell lines from adult rat cells. Cell stem cell 4: 11. 
Liu, H., F. Zhu, J. Yong, P. Zhang, P. Hou, H. Li, W. Jiang, J. Cai, M. Liu, K. Cui, X. Qu, T. 
Xiang, D. Lu, X. Chi, G. Gao, W. Ji, M. Ding, and H. Deng. 2008. Generation of Induced 
Pluripotent Stem Cells from Adult Rhesus Monkey Fibroblasts. Cell stem cell 3: 587-
590. 
Masui, S., Y. Nakatake, Y. Toyooka, D. Shimosato, R. Yagi, K. Takahashi, H. Okochi, A. 
Okuda, R. Matoba, A. A. Sharov, M. S. H. Ko, and H. Niwa. 2007. Pluripotency 
governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. 
Nat Cell Biol 9: 625-635. 
Matin, M. M., J. R. Walsh, P. J. Gokhale, J. S. Draper, A. R. Bahrami, I. Morton, H. D. Moore, 
and P. W. Andrews. 2004. Specific Knockdown of Oct4 and β2-microglobulin 
Expression by RNA Interference in Human Embryonic Stem Cells and Embryonic 
Carcinoma Cells. STEM CELLS 22: 659-668. 
Mitsui, K., Y. Tokuzawa, H. Itoh, K. Segawa, M. Murakami, K. Takahashi, M. Maruyama, M. 
Maeda, and S. Yamanaka. 2003. The homeoprotein Nanog is required for maintenance of 
pluripotency in mouse epiblast and ES cells. Cell 113: 631-642. 
54 
 
Miyamoto, K., T. Tsukiyama, Y. Yang, N. Li, N. Minami, M. Yamada, and H. Imai. 2009. Cell-
Free Extracts from Mammalian Oocytes Partially Induce Nuclear Reprogramming in 
Somatic Cells. Biology of Reproduction 80: 935-943. 
Nakagawa, M., M. Koyanagi, K. Tanabe, K. Takahashi, T. Ichisaka, T. Aoi, K. Okita, Y. 
Mochiduki, N. Takizawa, and S. Yamanaka. 2008. Generation of induced pluripotent 
stem cells without Myc from mouse and human fibroblasts. Nat Biotech 26: 101-106. 
Navarro, P., N. Festuccia, D. Colby, A. Gagliardi, N. P. Mullin, W. Zhang, V. Karwacki-Neisius, 
R. Osorno, D. Kelly, M. Robertson, and I. Chambers. 2012. OCT4/SOX2-independent 
Nanog autorepression modulates heterogeneous Nanog gene expression in mouse ES 
cells. EMBO J advance online publication. 
Niwa, H., J.-i. Miyazaki, and A. G. Smith. 2000. Quantitative expression of Oct-3/4 defines 
differentiation, dedifferentiation or self-renewal of ES cells. Nature genetics 24: 372-376. 
Pesce, M., and H. R. Schöler. 2001. Oct-4: Gatekeeper in the Beginnings of Mammalian 
Development. STEM CELLS 19: 271-278. 
Pfaffl, M. W., G. W. Horgan, and L. Dempfle. 2002. Relative expression software tool (REST) 
for group-wise comparison and statistical analysis of relative expression results in real-
time PCR. Nucleic acids research 30: e36. 
Rodriguez, R. T., J. M. Velkey, C. Lutzko, R. Seerke, D. B. Kohn, K. S. O’Shea, and M. T. 
Firpo. 2007. Manipulation of OCT4 Levels in Human Embryonic Stem Cells Results in 
Induction of Differential Cell Types. Experimental Biology and Medicine 232: 1368-
1380. 
Schöler, H. R., T. Ciesiolka, and P. Gruss. 1991. A nexus between Oct-4 and E1A: implications 
for gene regulation in embryonic stem cells. Cell 66: 291-304. 
Shi, Y., C. Desponts, J. T. Do, H. S. Hahm, H. R. Schöler, and S. Ding. 2008. Induction of 
Pluripotent Stem Cells from Mouse Embryonic Fibroblasts by Oct4 and Klf4 with Small-
Molecule Compounds. Cell stem cell 3: 568-574. 
Shimada, H., A. Nakada, Y. Hashimoto, K. Shigeno, Y. Shionoya, and T. Nakamura. 2010. 
Generation of canine induced pluripotent stem cells by retroviral transduction and 
chemical inhibitors. Molecular Reproduction and Development 77: 2-2. 
Silva, J., O. Barrandon, J. Nichols, J. Kawaguchi, T. W. Theunissen, and A. Smith. 2008. 
Promotion of Reprogramming to Ground State Pluripotency by Signal Inhibition. PLoS 
Biol 6: e253. 
Simonsson, S., and J. Gurdon. 2004. DNA demethylation is necessary for the epigenetic 
reprogramming of somatic cell nuclei. Nat Cell Biol 6: 984-990. 
Staszkiewicz, J., R. A. Power, L. L. Harkins, C. W. Barnes, K. L. Strickler, J. S. Rim, K. R. 
Bondioli, and K. J. Eilersten. 2013. Silencing Histone Deacetylase-Specific Isoforms 
55 
 
Enhances Expression of Pluripotency Genes in Bovine Fibroblasts. Cellular 
Reprogramming. 
Stein, B., Luong, Shi, Smith, Vasquez. 2011. Human Stem Cell Technology and Biology "A 
Research Guide and Laboratory Manual". John Wiley & Sons, Inc., Hoboken, New 
Jersey. 
Storm, M. P., H. K. Bone, C. G. Beck, P.-Y. Bourillot, V. Schreiber, T. Damiano, A. Nelson, P. 
Savatier, and M. J. Welham. 2007. Regulation of Nanog Expression by Phosphoinositide 
3-Kinase-dependent Signaling in Murine Embryonic Stem Cells. J. Biol. Chem. 282: 
6265-6273. 
Tachibana, M., K. Sugimoto, M. Nozaki, J. Ueda, T. Ohta, M. Ohki, M. Fukuda, N. Takeda, H. 
Niida, H. Kato, and Y. Shinkai. 2002. G9a histone methyltransferase plays a dominant 
role in euchromatic histone H3 lysine 9 methylation and is essential for early 
embryogenesis. Genes Dev 16: 1779-1791. 
Takahashi, K., K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, and S. Yamanaka. 
2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. 
Cell 131: 861-872. 
Takahashi, K., and S. Yamanaka. 2006. Induction of Pluripotent Stem Cells from Mouse 
Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 126: 663-676. 
Takao, Y., T. Yokota, and H. Koide. 2007. β-Catenin up-regulates Nanog expression through 
interaction with Oct-3/4 in embryonic stem cells. Biochemical and Biophysical Research 
Communications 353: 699-705. 
Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. International 
Immunology 17: 1-14. 
Taranova, O. V., S. T. Magness, B. M. Fagan, Y. Wu, N. Surzenko, S. R. Hutton, and L. H. 
Pevny. 2006. SOX2 is a dose-dependent regulator of retinal neural progenitor 
competence. Genes & Development 20: 1187-1202. 
Thomson, J. A., J. Itskovitz-Eldor, S. S. Shapiro, M. A. Waknitz, J. J. Swiergiel, V. S. Marshall, 
and J. M. Jones. 1998. Embryonic Stem Cell Lines Derived from Human Blastocysts. 
Science 282: 1145-1147. 
Till, J. E., and E. A. McCulloch. 1961. A Direct Measurement of the Radiation Sensitivity of 
Normal Mouse Bone Marrow Cells. Radiation Research 14: 213-222. 
Uematsu, S., and S. Akira. 2007. Toll-like Receptors and Type I Interferons. Journal of 
Biological Chemistry 282: 15319-15323. 
Van Tendeloo, V. F. I., P. Ponsaerts, F. Lardon, G. Nijs, M. Lenjou, C. Van Broeckhoven, D. R. 
Van Bockstaele, and Z. N. Berneman. 2001. Highly efficient gene delivery by mRNA 
electroporation in human hematopoietic cells: superiority to lipofection and passive 
56 
 
pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of 
dendritic cells. Blood 98: 49-56. 
Wagers, A. J., and I. L. Weissman. 2004. Plasticity of Adult Stem Cells. Cell 116: 639-648. 
Warren, L., P. D. Manos, T. Ahfeldt, Y.-H. Loh, H. Li, F. Lau, W. Ebina, P. K. Mandal, Z. D. 
Smith, A. Meissner, G. Q. Daley, A. S. Brack, J. J. Collins, C. Cowan, T. M. Schlaeger, 
and D. J. Rossi. 2010. Highly Efficient Reprogramming to Pluripotency and Directed 
Differentiation of Human Cells with Synthetic Modified mRNA. Cell stem cell 7: 618-
630. 
Wei, Z., Y. Yang, P. Zhang, R. Andrianakos, K. Hasegawa, J. Lyu, X. Chen, G. Bai, C. Liu, M. 
Pera, and W. Lu. 2009. Klf4 Interacts Directly with Oct4 and Sox2 to Promote 
Reprogramming. STEM CELLS 27: 2969-2978. 
Wernig, M., A. Meissner, J. P. Cassady, and R. Jaenisch. 2008. c-Myc Is Dispensable for Direct 
Reprogramming of Mouse Fibroblasts. Cell stem cell 2: 10-12. 
Williamson, K. A., A. M. Hever, J. Rainger, R. C. Rogers, A. Magee, Z. Fiedler, W. T. Keng, F. 
H. Sharkey, N. McGill, C. J. Hill, A. Schneider, M. Messina, P. D. Turnpenny, J. A. 
Fantes, V. van Heyningen, and D. R. FitzPatrick. 2006. Mutations in SOX2 cause 
anophthalmia-esophageal-genital (AEG) syndrome. Human Molecular Genetics 15: 
1413-1422. 
Wilmut, I., A. E. Schnieke, J. McWhir, A. J. Kind, and K. H. S. Campbell. 1997. Viable 
offspring derived from fetal and adult mammalian cells. Nature 385: 810-813. 
Wood, H. B., and V. Episkopou. 1999. Comparative expression of the mouse Sox1, Sox2 and 
Sox3 genes from pre-gastrulation to early somite stages. Mechanisms of Development 
86: 197-201. 
Wu, Q., X. Chen, J. Zhang, Y.-H. Loh, T.-Y. Low, W. Zhang, W. Zhang, S.-K. Sze, B. Lim, and 
H.-H. Ng. 2006. Sall4 Interacts with Nanog and Co-occupies Nanog Genomic Sites in 
Embryonic Stem Cells. Journal of Biological Chemistry 281: 24090-24094. 
Xie, H., M. Ye, R. Feng, and T. Graf. 2004. Stepwise Reprogramming of B Cells into 
Macrophages. Cell 117: 663-676. 
Yang, X., S. L. Smith, X. C. Tian, H. A. Lewin, J. P. Renard, and T. Wakayama. 2007. Nuclear 
reprogramming of cloned embryos and its implications for therapeutic cloning. Nature 
genetics 39: 295-302. 
Yu, J., K. F. Chau, M. A. Vodyanik, J. Jiang, and Y. Jiang. 2011. Efficient feeder-free episomal 
reprogramming with small molecules. PLoS One 6: e17557. 
Yu, J., M. A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J. L. Frane, S. Tian, J. Nie, G. 
A. Jonsdottir, V. Ruotti, R. Stewart, I. I. Slukvin, and J. A. Thomson. 2007. Induced 
57 
 
Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Science 318: 1917-
1920. 
Zaehres, H., M. W. Lensch, L. Daheron, S. A. Stewart, J. Itskovitz-Eldor, and G. Q. Daley. 2005. 
High-Efficiency RNA Interference in Human Embryonic Stem Cells. STEM CELLS 23: 
299-305. 
Zhao, S., J. Nichols, A. G. Smith, and M. Li. 2004. SoxB transcription factors specify 
neuroectodermal lineage choice in ES cells. Molecular and Cellular Neuroscience 27: 
332-342. 
Zhou, H., S. Wu, J. Y. Joo, S. Zhu, D. W. Han, T. Lin, S. Trauger, G. Bien, S. Yao, Y. Zhu, G. 
Siuzdak, H. R. Scholer, L. Duan, and S. Ding. 2009. Generation of induced pluripotent 
stem cells using recombinant proteins. Cell stem cell 4: 381-384. 
Zhou, Y. Y., and F. Zeng. 2013. Integration-free Methods for Generating Induced Pluripotent 

































APPENDIX A  
PROTOCOLS 
 
MMESSAGE MMACHINE® PROTOCOL 
 
1. Thaw frozen reagents. Place RNA Polymerase Enzyme Mix on ice. Vortex the 10X 
Reaction Buffer and 2X NTP/CAP to ensure contents are resuspended and place the 2X 
NTP/CAP on ice. Centrifuge in microfuge briefly prior to removing caps. 
2. Assemble transcription reaction at room temperature. Add the water and ribonucleotides to 
the tube prior to adding the 10X Reaction Buffer, followed by the addition of linear DNA 
template and Enzyme Mix.  
a. 10 µl 2X NTP/CAP, 2 µl 10X Reaction Buffer, 6 µl (0.1-1ug) Linear DNA 
template, 2 µl Enzyme Mix 
3. Mix thoroughly by gently flicking the tube or pipetting up and down. Centrifuge briefly to 
bring the reaction to the bottom of the tube.  
4. Incubate at 37°C for 2 hours for maximum yield (1 hour incubation has an 80% yield) 
5. OPTIONAL: Add 1 µl TURBO DNase and mix thoroughly. Incubate 15 min at 37°C to 
remove template DNA.  
6. Reaction goes immediately into Poly(A) Tailing Kit 
AMBION® POLY(A) TAILING KIT PROTOCOL  
1. Begin with a completed, room temperature, DNase-treated mMessage mMachine reaction 
(20 µl in 1.5ml tube). DO NOT add EDTA to the reaction to inactivate the DNase. 
2. Remaining at room temperature, add the following reagents in the order they are listed to 
the 20 µl mMessage mMachine reaction: 
a. 20 µl mMessage mMachine reaction, 36 µl Nuclease-free water, 20 µl 5X E-PAP 
Buffer, 10 µl 25 mM MnCl2, 10 µl 10 mM ATP 
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3. Remove 0.5 µl of the reaction prior to adding the enzyme to run as a control on a gel 
against the tailed reaction. 
4. Add 4 µl of E-PAP and mix gently. The final reaction should be 100ul.  
5. Incubate for 1 hour at 37°C. 
6. Reaction can go directly into the MEGAclear™ Kit procedure or can be placed on ice or 
stored at -20°C until for later use.  
7. During the incubation period, prepare a denaturing agarose gel for electrophoresis. The 
agarose-formaldehyde gel is used to compare the tailed reaction to the untailed original.  
a. Heat the samples to 75°C for 10 minutes. 
b. Load the samples onto the gel and run in 1X MOPS buffer at 5 volts/cm until the 
bromophenol blue dye is near the bottom of the gel.  
c. Examine in a UV light. The tailed reaction should be approximately 150 bases 
longer than the untailed original.   
FOMALDEHYDE AGAROSE GEL ELECTROPHORESIS 
1.2 g agarose 
10 ml 10X FA gel buffer (components listed below) 
Add RNase-free water to 100ml 
1. Heat to melt agarose. Cool to 65°C in a water bath.  
2. Add 1.8 ml of 37% (12.3 M) formaldehyde and 1 ul of a 10 mg/ml ethidium bromide stock 
solution. Mix thoroughly and pour into gel mold.  
3. Equilibrate the gel for at least 30 minutes in 1X FA gel running buffer prior to running the 
gel.  
4. Run the gel at 5-7 V/cm in 1X FA gel running buffer.  
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MEGACLEAR™ KIT PROCEDURE 
1. Begin with 100 μl Poly(A) Tailing Reaction (or bring RNA sample up to 100 μl by adding 
Elution Solution and mix gently). 
2. Add 350 μl of Binding Solution Concentrate and mix gently by pipetting.  
3. Add 250 μl of 100% ethanol and mix gently by pipetting.  
4. Insert a filter cartridge into a Collection and Elution tube supplied by the manufacturer.  
5. Apply the RNA sample to the filter cartridge. 
6. Centrifuge at 10,000-15,000 x g for 1 minute to pass mixture through the filter.  
7. Discard flow-through and reuse the Collection and Elution Tube during the following wash 
steps. 
8. Be sure ethanol has been added to the wash solution before use. Apply 500 µl Wash 
Solution and centrifuge at 10,000-15,000 x g for 1 minute to pass the Wash Solution 
through the filter. 
9. Repeat with a second 500 µl Wash Solution. 
10. Discard flow-through and centrifuge for 30 seconds at 10,000-15,000 x g to remove any 
Wash Solution.  
11. Elute RNA with 50 µl of Elution Solution 
a. OPTION 1: Place filter cartridge into a new Collection/Elution Tube. Apply 50 µl 
Elution Solution to the center of the filter and close the cap. Incubate in heat block 
at 65-70°C for 5-10 minutes. Recover eluted RNA by centrifuging for 1 minute at 
10,000-15,000 x g. *To maximize recovery, repeat with a second 50 µl of elution 
solution in the same tube.  
b. OPTION 2: Pre-heat 110 µl of Elution Solution to 95°C. Apply 50 µl of pre-
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heated Elution Solution to the center of the filter and close the cap. Centrifuge for 
1 minute at 10,000-15,000 x g. *To maximize recovery, repeat with a second pre-
heated 50 µl of Elution Solution into the same tube. 
LIPOFECTAMINE® RNAiMAX REAGENT TRANSFECTION PROTOCOL 
1. Plate target cells 24-hours prior to transfection in 500 µl growth medium each well of a 24-
well plate. Cell should be 50-70% confluent for transfection. 
2. Dilute ivtRNA in 50 ul of Opti-MEM® I Medium without serum per well in a 15 ml 
conical tube and mix gently. Label as Tube 1. 
3. Gently mix Lipofectamine® RNAiMAX Reagent prior to use. Dilute 1 µl of 
Lipofectamine® RNAiMAX Reagent in 50 µl of Opti-MEM® I Medium per well in a 
separate 15 ml conical tube. Label as Tube 2. 
4. Combine the contents of Tube 2 into the contents of Tube 1 and mix gently. Incubate for 
15 minutes at room temperature.  
5. Add adequate amount of RNA-Lipofectamine® complexes to each well and mix gently by 
rocking the plate back and forth several times. The total volume should be roughly 600 
µl.  
6. Incubate in CO2 incubator at 37°C. 
7. Change medium 4-6 hours after transfection.  
8. Repeat transfection as desired. 
R&D SYSTEMS® iMEF PLATING PROTOCOL 
Catalog Number: PSC001, irradiated primary mouse embryonic fibroblast cells at passage 3, 
approximately 6 x 106 cells per vial, stored in LN  
*Feeder layers should be plated at least 24 hours prior to seeding target cells. 
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1. Coat surface of dish with 0.1% sterile gelatin for 15 minutes. 
2. Warm iMEF medium (high glucose DMEM, 10% fetal bovine serum, 2 mM L-Glutamine) 
to 37°C. 
3. Thaw the cells quickly by warming vial in 37°C water bath. Immediately transfer contents 
of vial to 15 mL conical tube containing 5 mL of pre-warmed iMEF medium. Rinse vial 
with 1 mL of pre-warmed medium to ensure removal of all cells from vial.  
4. Pellet cells at 200 x g for 5 minutes. 
5. Remove excess gelatin from wells immediately prior to plating iMEF cells.  
6. Resuspend iMEF cells in pre-warmed iMEF medium and transfer appropriate density of 
cells depending on the surface area of dish (approximately 1 x 106 cells/60 mm plate).  
7. Incubate overnight in a 5% CO2 incubator at 37°C. 
DYNABEADS® RNA ISOLATION PROTOCOL  
1. Harvest cells from culture flask and pellet as per standard procedure 
2. Add 300 µl of Lysis/Binding buffer (100 mM Tris-HCL [pH 7.5], 500 mM LiCl, 10 mM 
EDTA [pH 8], 1% LiDS, 5 mM dithiothreitol [DTT]) to fresh cell pellet.  
3. DNA-shearing step is advised if sample is greater than 500,000 cells. Strip cells using a 21-
gauge needle and a 1 ml syringe. 
4. Prepare 50 µl Dynabeads Oligo (dT)25 per manufacturer instructions (Invitrogen Dynal As, 
Oslo, Norway, Cat.no. 610.11/610.12). 
5. Add sample lysate to pre-washed Dynabeads (pre-washed in lysis/binding buffer). 
6. Resuspend beads completely into sample lysate and incubate with continuous mixing 
(rolling mixer) for 5 minutes at room temperature. This allows the polyA tail to hybridize 
to the beads.  
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7. Place the vial on the magnet for 2 min and remove supernatant. If viscous, increase time to 
10 minutes.  
8. Wash beads/mRNA complex twice in 600 µl Washing Buffer A (10 mM Tris-HCl [pH 
7.5], 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS) at room temperature. Place on magnet to 
separate beads from solution between each wash step.  
9. Wash beads/mRNA complex in 300 µl Washing Buffer B (10 mM Tris-HCl [pH 7.5], 0.15 
M LiCl, 1 mM EDTA) at room temperature. Use the magnet to separate the beads from 
the solution.  
10. Elute the RNA from the beads by adding 15 µl of nuclease-free water, incubate at 70°C 
for 2 min. Immediately place tube on magnet, and transfer supernatant to a new RNase-
free tube. 
11. Use sample directly into cDNA protocol. 
iSCRIPT CDNA SYNTHESIS PROTOCOL 
1. Add 4 µl of iScript reaction mix and 1 µl of reverse transcriptase to a 15-µl RNA sample 
from previous DYNABEADS isolation in a PCR tube (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA). 
2. Place PCR tubes into thermocycler and run cDNA protocol. 
a. 5 min at 25°C, 30 min at 42°C, and 5 min at 85°C, (final hold at 4°C) 
RNEASY® PLUS MINI KIT (QIAGEN) 
 
1. Harvest cells by trypsinization and pellet. Completely remove supernatant. 
2. Disrupt cells with the addition of Buffer RLT Plus. Loosen pellet by flicking prior to 
adding 350 µL Buffer RLT. Mix by vortexing or pipetting up and down. 
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3. Homogenize lysate by passing it through a 20-gauge needle 5 times in an RNase-free 1ml 
syringe. 
4. Transfer homogenized lysate to a gDNA Eliminator spin column placed within 2 ml 
collection tube. Centrifuge 30 seconds at 8000 x g and discard column. Collection tube 
should contain flow-through to be used in following steps. 
5. Add 350 µl of 70% ethanol to the flow-through in the collection tube. Mix by pipetting 
up and down. 
6. Transfer 700 µl of sample to RNeasy® spin column placed within a 2 ml collection tube 
and close lid. Centrifuge for 15 seconds at 8000 x g. Discard flow-through. 
7. Add 700 µl Buffer RW1 to the RNeasy® spin column placed into previous collection 
tube. Close lid and centrifuge for 15 seconds at 8000 x g. Discard flow-through. 
8. Add 500 µl Buffer RPE to RNeasy® spin column and close lid. Centrifuge for 15 
seconds at 8000 x g. Discard flow-through.  
9. Add 500 µl Buffer RPE to RNeasy® spin column and close lid. Centrifuge 2 minutes at 
8000 x g to ensure removal of ethanol. Remove column carefully not coming in contact 
with flow-through.  
10. Place RNeasy® spin column into a new 2 ml collection tube and add 30 µl RNase-free 
water directly to spin column membrane. Close lid and centrifuge for 1 minute at 8000 x 
g for RNA elution. Repeat with an additional 30 µl to maximize recovery.  
RT-PCR PROTOCOL 
 
1. Each reaction is carried out in a total of 50 µl. Mix 25 µl of JumpStart™ REDTaq® 
ReadyMix™ PCR Reaction Mix (Sigma Aldrich), 2 µl of (10 mM) forward primer, 2 µl 
65 
 
of (10 mM) reverse primer, 11 µl of water, and 10 µl of sample cDNA. Prepare master 
mixes prior to avoid repeated pipetting.  
2. Place tubes into thermocycler with the following program: 
a. Thermocycler Program 
Hotstart 94°C  2 minutes 
Denature 94°C  30 seconds 
Anneal  60°C  30 seconds 
Extend  72°C  1 minute 
30 CYCLES 
Final Ext 72°C  5 minutes 
Hold  4°C  indefinitely 
 
b. Annealing temperature is specific to primers used in reaction. 
3. Remove tubes from thermocycler and add 25 µl of each PCR product to a 1% agarose gel 
for electrophoresis.  
qRT-PCR PROTOCOL 
1. Set up plate template.  
2. Prepare master mixes for each gene. Each reaction is carried out in a 20 µl reaction (10 ul 
of SsoFast™ Evagreen Supermix (Bio-Rad Laboratories, Inc. Hercules, CA, USA), 4 µl 
of nuclease-free water, 1 µl of (10 mM) forward primer, 1 μl of (10 mM) reverse primer, 
and 4 µl of sample cDNA, calibrator cDNA, or water as negative control.  
3. Add 20 µl of each reaction into a single well of a 96-well plate with the designated plate 
set-up. Cover with sealing tape supplied by plate manufacturer. Be sure to completely 
seal each well using the rubber scraper or tool provided.  
4. Place 96-well plate into thermocycler and run the following program: 
a. Thermocycler Program 
Cycle Repeats Step  Time  T° Melt Curve 
       1  1  1  1 min 95      
               2  40  1  5 sec  95 
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                  2  30 sec 60 
               3  1  1  1 min 95 
       4  1  1  1 min 55    
        5  80  1  10 sec 55 yes, +5° each repeat 
 
5. Evaluate post-run data for analysis and melting curve. If a calibrator dilution was  
performed, evaluate Standard Curve Efficiency, PCR Amp/Cycle graph, and Melt Curve 
Analysis.  
Plasmid Preparation 
Stab cultures containing plasmids encoding desired sequences were obtained from 
Addgene. The cultures were streaked on agar plates containing ampicillin 100ug/ml 
concentration. Clones were chosen from each plate by inserting a pipette tip into a single colony 
and inserting it into 3ml of Terrific Broth containing ampicillin 100ug/ml in a 15 ml culture tube. 
The selected clones were prepared as mini-preps with overnight culture at 37° C shaking at 225 
RPM in C24 Incubator Shaker (New Brunswick Scientific, Classic Series).  
Mini Prep Isolation 
All tubes were cloudy post-incubation, indicating growth of the selected clones. Mini-
preps were performed on all tubes using SIGMA GenElute Plasma Mini Prep Kit. Cells were 
pelleted from 1.5 ml of previous overnight culture for 1 minute at 12,000 x g in table top 
centrifuge (Thermo, Heraeus Pico 17 Centrifuge). Supernatant was discarded and cells were 
resuspended by pipetting up and down in 200 μl of Resuspension Solution provided in the kit. 
The cells were then lysed with the addition of 200 μl of Lysis Solution and inverting the tubes 
gently to mix. The tubes were then allowed to equilibrate for ≤ 5 minutes. The cleared lysate was 
then prepared for isolation with the addition of 350 μl of Neutralization Solution and inverted 4-6 
times to mix. The tubes were then centrifuged at maximum speed of 13,000 x g for 10 minutes. 
The binding column was prepared by adding 500 μl of Column Preparation Solution and 
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centrifuged at 12,000 x g for 1 minute. The cleared lysate was then transferred to the prepared 
binding columns to bind the plasmid DNA for isolation. The column containing the cleared 
lysate was centrifuged for 1 minute at 12,000 x g and the flow-through was discarded. 
Contaminants were removed by adding 750 μl of Wash Solution (ethanol added prior to first use 
of kit) to the column followed by centrifugation at 12,000 x g for one minute. The flow through 
was discarded and was centrifuged for an additional minute to remove to dry the column. Each 
column was transferred to a new collection tube and the plasmid DNA was eluted in 75ul of 
molecular grade water and was stored at -20°C. 
Clone Selection 
Diagnostic cuts in the DNA were performed with restriction enzyme XbaI on each clone. 
A master mix was prepared when applicable (buffer provided by manufacturer, molecular grade 
water, XbaI restriction enzyme) for all mini-prep isolations. The master mix was then divided 
and 85ul was placed in 12 separate 1.5 ml centrifuge tubes followed with the insertion of 15ul 
DNA for each clone. The digest was performed in a hot water bath of 37°C for 1 hour and 15 
minutes. The tubes were removed from the water bath and 15ul of loading buffer was added to 
each tube and mixed gently by pipetting up and down. A 1% agarose gel was prepared and 25 μl 
of each digest were loaded into the wells for electrophoresis evaluation.  The bands were 
evaluated with the additional 1 kilobase (1Kb) and 100 base pair (100bp) ladders added to the 
outside lanes. The correct diagnosis was reached with the GFP plasmid dropping out a 904 bp 
sequence and OCT4 plasmid dropping out a 1200 bp sequence.  
Clones were selected and were removed from the refrigerator and 2 ml of Terrific Broth 
containing ampicillin was added. The cultures were allowed to shake at 225 RPM at 37°C for 1 
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hour. The remaining 50 ml of broth was then added and the culture was incubated overnight at 
the same conditions in a 500 ml Erlenmeyer flask.  
Midi Prep Plasmid Purification 
Qiagen Midi Preps were then carried out by pelleting 50 ml of overnight culture at    6000 
x g for 15 minutes at 4°C. Supernatant was removed and the pellet was resuspended in 4 ml of 
Buffer P1, followed by the addition of 4 ml of Buffer P2. The mix was thoroughly made 
homogenous by inverting vigorously 5 times followed by 5-minute incubation at room 
temperature. The QIAfilter Cartridge was prepared during this incubation period. Buffer P3 was 
added at 4 ml and mix thoroughly by inverting vigorously 5 times. The lysate was poured into 
the barrel of the QIAfilter Cartridge and was incubated for 10 minutes at room temperature. 
QIAGEN-tip 100 was equilibrated by adding 4 ml of Buffer QBT. This buffer was released by 
gravity flow. The lysate in the barrel of the QIAfilter Cartridge was expelled into the prepared 
QIAGEN-tip 100 by inserting the plunger into the barrel and filtering the lysate into the prepared 
tip. The cleared lysate was allowed to flow through the tip by gravity flow, followed by 2 x 10 
ml wash with Buffer QC. The DNA was eluted with 5 ml of Buffer QF and precipitated with the 
addition of 3.5 ml of room-temperature isopropanol. The solution was mixed and centrifuged at 
15,000 x g for 30 minutes at 4°C. The supernatant was decanted and the DNA pellet was washed 
with 2 ml of room temperature 70% ethanol and centrifugation at 15,000 x g for 10 minutes. The 
supernatant was decanted and the pellet was allowed to air-dry for 5-10 minutes. The DNA was 
re-dissolved in 500 μl TE for each preparation and placed in -20°C for storage. DNA was 
quantified by absorbance by SmartSpec™ Plus Spectrophotometer (BioRad) and TE buffer.  
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Diagnostic restriction digests were performed on Midi Preps for validation using XbaI 
restriction enzyme. The digests were performed overnight at 37°C in a warm water bath. The 
digests were evaluated using gel electrophoresis and a 1% agarose gel.  
Synthesizing Messenger RNA 
Plasmids containing template sequence were linearized using restriction enzyme XbaI. 
The restriction digest was terminated with the addition of 1/10th the volume of 3 M Na acetate 
and 2 volumes of ethanol. The solution was mixed well and stored in -20°C for 15 minutes. The 
DNA was pelleted by centrifugation at 13,000 x g for 15 minutes. The supernatant was removed 
and the tube centrifuged again, and any residual fluid was removed with a fine-tipped pipet. The 
pellet was resuspended in 6 μl TE and was carried over into the mMESSAGE mMACHINE Kit 
(High Yield Capped RNA Transcription Kit). The reaction was performed in a total of 20 μl, 
including 10 μl of 2X NTP/CAP, 2 μl 10X Reaction Buffer, 6 μl linear template DNA, and 2 μl 
of Enzyme Mix. The solution was mixed by gently flicking the tube and was incubated for 2 
hours at 37°C in a warm water bath.  
The previously completed 20ul reaction was carried over to the Poly (A) Tailing Kit 
(Applied Biosystems AM1350) for further RNA packaging.  The tailing agents were added in 
order (36 μl Nuclease-free water, 20 μl 5X E-PAP Buffer, 10 μl 25 mM MnCl2, and 10 ul mM 
ATP, 4 μl E-PAP) to the room temperature 20ul mMessage mMachine reaction yielding a total 
of 100 μl. This tailing reaction was incubated at 37°C for 1 hour in a warm water bath.  
The tailing reaction was purified using MEGAclear Kit (Applied Biosystems AM1908). 
The RNA sample was first subjected to 350 μl of Binding Solution Concentrate and was mixed 
gently by pipetting up and down. 250 μl of 100% ethanol was added and mixed gently. A filter 
cartridge was inserted into a Collection Tube supplied by the kit. The RNA mixture was loaded 
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into the filter cartridge and is centrifuged for 1 minute at 13,000 x g in tabletop centrifuge. The 
flow-through was discarded and the same Collection Tube was used for the washing steps. The 
Wash Solution (previously added ethanol as directed) was applied 2 x 500 μl with centrifugation 
and discarding flow-through. The tubes were centrifuged once again to ensure removal of all 
wash solution. The RNA was then eluted into a new Collection Tube by adding 50 μl of pre-
warmed (95°C) TE to the cartridge. The tube was centrifuged at 13,000 x g for 1 minute. This 
step was repeated within the same collection tube to maximize RNA recovered.  
The ivtRNA was then quantified using NanoVue Spectrophotometer using TE as the 
blank for the machine. The solution was then diluted with an adequate volume of TE to obtain a 
working concentration of 100 ng/ml.  
Expansion of Cell Cultures 
Established bovine fetal fibroblast cell line BEZ2 (passage 2-5) was removed from liquid 
nitrogen and quickly placed in warm water bath at 37°C until thawed. Cells were removed from 
the cryovial and placed into 15ml conical tube containing 5ml of Dulbecco’s Modified Eagle 
Medium (DMEM), 10% Fetal Bovine Serum (FBS), and 1% penicillin/streptomycin (P/S). The 
cryovial was then rinsed with 1ml of the same medium to ensure removal of all cells. The conical 
tube was then centrifuged at 350 x g for 5 minutes to establish a cell pellet. The supernatant was 
removed and the cells were resuspended in 10 ml of medium and placed into a T75 for 
expansion. The T75 culture flask was incubated in 5% CO2 at 37°C for two days. Once the cells 
were approaching confluency they were passaged with Trypsin (0.25 EDTA) and plated into 24-
well plates at recommended seeding density of 50,000 cells per well. The plates were then 





Previously plated bovine fetal fibroblasts reached 70% confluency and were ready to be 
transfected. Specific ivtRNA was diluted in Opti-MEM I Medium at in 15ml conical tubes. 
Lipofectamine RNAiMAX Reagent was diluted 1ul per 50ul Opti-MEM I Medium in a 15 ml 
conical tube. The diluted RNA complex was then combined with the Lipofectamine RNAiMAX 
Reagent and incubated for 15-20 minutes at room temperature. The RNAi-duplex-Lipofectamine 
RNAiMAX Reagent complexes were added to each well containing cells for transfection. The 
final volume was roughly 600ul per well. The plate was moved back and forth several times to 
ensure even distribution of ivtRNA-Lipofectamine mixture over all cells attached to well. The 
cells were incubated in 5% CO2 at 37°C for 24 hours and all media was changed daily. 
Flow Cytometry 
Culture medium was aspirated from all wells, followed by a wash with PBS without calcium and 
magnesium. PBS was aspirated and cells were detached using Trypsin (0.25 EDTA). Normal 
growth medium containing serum was added to inactivate the Trypsin. The contents of each well 
were transferred into labeled 1.7ml centrifuge tubes. The cells were centrifuged at 400 x g for 8 
minutes. The supernatant was completely aspirated and the cells were resuspended in 1ml PBS 
(without calcium and magnesium). A small volume (10 μl) was removed from each sample and 
placed in 90 μl of PBS for cell counting. The flow cytometer was prepared for sampling by the 
routine setup protocol prior to running any samples. Once the flow cytometer was ready, each 
sample was evaluated for 5 minutes with slow fluidics settings.   
RNA Isolation 
The cells were trypsinized from each well and treatment groups were combined into one 
15ml tube each for unmodified ivtRNA experiments. The cells were isolated and evaluated by 
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well for all other experiments. The cells were pelleted and resuspended in 1 ml PBS without 
calcium and magnesium. This volume was transferred to 1.5 ml tubes and pelleted again at 400 x 
g for 8 minutes using a table top centrifuge. The mRNA was harvested using DYNA beads 
following the “mini” protocol. The mRNA was eluted in 15 ml of dH2O, which went 
immediately into iScript to be converted into cDNA per manufacturer instructions, yielding a 
final volume of 20 μl. The final 20 μl reaction was divided in half for subsequent PCR reactions.  
Polymerase Chain Reaction 
PCR was used to determine the endogenous expression of bovine OCT4 compared to 
exogenous expression of human OCT4. Each PCR reaction consisted of 25 μl Jumpstart Red 
Mix, 2 μl forward primer, 2 μl reverse primer, 10 μl cDNA, and 11 μl dH20 for a total of 50 μl. 
The final PCR products were evaluated by gel electrophoresis using 1.2% agarose gel including 
100bp ladder on the outside lanes.  
Establishing 4-Factor and 3-Factor Cocktails 
A KMOS (KLF4, cMYC, OCT4, SOX2) and KOS (KLF4, OCT4, SOX2) cocktails were 
prepared using the working concentrations of each of the ivtRNA solutions. OCT4 was held at 
3X the concentration of the other factors.  
Calibrator Development 
A positive control is required during the analysis of gene expression through quantitative 
PCR. This positive control normally comes in the form of a calibrator. Total RNA was isolated 
from BEZ2 P7 using RNeasy® Plus Mini Kit from Qiagen per manufacturer instructions. The 
RNA was immediately converted into cDNA using iScript. The calibrator is made up of cDNA 
from the target cells “spiked” with purified PCR product (QIAquick PCR Purification Kit) 
encoding specific genes. These genes include both the genes of interest, OCT4, SOX2, and 
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NANOG, as well as housekeeping genes PAP and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The calibrator contains genes of interest at a final concentration of 2pg/μl and the 
housekeeping genes at a final concentration of 0.2pg/μl. 
qPCR 
Quantitative PCR was used to evaluate gene expression in the target cells. Total RNA 
was extracted from cells in all wells using DYNA beads according to the manufacturer’s 
instructions. The final elution into 15ul dH2O was placed directly into a complementary DNA 
reaction following the manufacturer’s instructions, with a final volume of 20ul per sample. Prior 
to setting up PCR reactions, each sample was diluted with the addition of 50ul dH2O. Each PCR 
reaction contained 4ul of sample cDNA. Measurements were carried out in triplicates and a no-
template reaction as a negative control. Amplification, standard curves and gene expression 
efficiency were normalized against housekeeping genes PAP and GAPDH as internal controls.  
Table A.1 PCR Primers 
Primer Sequence Amplicon  
Length 
Accession # 
Oct4 sense GGTTCTCTTTGGAAAGGTGTTC 223 NM_174580.2 
Oct4 antisense  ACACTCGGACCACGTCTTTC 
Sox2 sense  AGGACTGAGAGAAAGAAGAAGAG 164 NM_001105463.2 
Sox2 antisense AAGAAAGAGGCAAACTGGAATC 
Nanog II sense AATTCCCAGCAGCAAATCAC 215 NM_001025344.1 
Nanog II antisense CCCTTCCCTCAAATTGACAC 
Poly A sense AAGCAACTCCATCAACTACTG 169 X63436 
Poly A antisense ACGGACTGGTCTTCATAGC 
GAPDH sense CCTTCATTGACCTTCACTACATGGTCTA 127 U85042 
GAPDH antisense TGGAAGATGGTGATGGCCTTTCCATTG 
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Table A.2: GFP ivtRNA Quantification 
 Concentration (ug/ml) A260/A280 
GFP (1) 656.8 2.477 
   
Table A.3 ivtRNA Concentrations 
 RNAi duplex concentration 
*24-well plate 
Volume per well (μl) 
Low 1 pmol (140ng) 1.4 
Medium 2 pmol (280ng) 2.8 
High 4 pmol (560ng) 5.6 
   
 
Table A.4 Plasmid DNA Quantification 
 Concentration (ug/ml) A260/A280 
OCT4 12.3314 1.7169 
GFP 13.2331 1.7738 
 
 
Table A.5: hOCT4 ivtRNA Spectrophotometer Quantification 
 Concentration (ug/ml) A260/A280 
hOCT4 (1) 596.0 2.656 
hOCT4 (2) 592.4 2.649 




Table A.6 ivtRNA Concentrations 
 RNAi duplex concentration 
*24-well plate 
µl per well 
Low 1 pmol (140ng) 1.4 
Medium 2 pmol (280ng) 2.8 
High 4 pmol (560ng) 5.6 
   
 
Table A.7 Plasmid DNA Quantification 
 Concentration (ug/ml) A260/A280 









Table A.8: SOX2, KLF4, cMYC ivtRNA Quantification 
Gene Concentration (ug/ml) A260/A280 
SOX2  259.2 3.057 
KLF4  402.4 2.661 
cMYC  228.4 2.266 
OCT4 260.3 2.936 





Table A.9 Purified PCR Products 
Gene Concentration (ng/ml) A260/A280 
OCT4  4.7 1.500 
SOX2 4.9 1.485 
NANOG 15.5 1.667 
PAP 14.8 1.561 



































MEDIA FORMULATIONS AND STOCK SOLUTIONS 
 
Table B.1 List of Plasmids  
 
Plasmid Clones Selected 
From Plates 
Clones Used for 
Mini-Prep 
Clone Selected 
26822pcDNA3.3_GFP 1-6 1-6 1 
26816pcDNA3.3_OCT4 1-6 1-6 1 
26817pcDNA3.3_SOX2 1-6 1-3, 6 2 
26818pcDNA3.3_cMYC 1-6 1-6 6 






NORMAL GROWTH MEDIUM 
DMEM (Dulbecco’s Modified Eagle Medium) 
10% FBS (Fetal Bovine Serum; or Bovine Calf Serum (BCS) for non-experimental cell culture) 
1% P/S (Penicillin/ Streptomycin) 
iMEF CULTURE MEDIUM 
DMEM 














1000 U/ml LIF 
4 ng/ml bFGF 





1000 U/ml LIF 
4 ng/ml bFGF 
0.5 µM PD0325901 
3 µM CHIR99021 
1.8 µM NuP0148  
 
10X FA Gel Buffer Composition 
 200 mM 3-[N-morpholino]propanesulfonic acid (MOPS) (free acid) 
50 mM sodium acetate 





1X FA Gel Running Buffer Composition 
100 ml 10X FA gel buffer 
20 ml 37% (12.3 M) formaldehyde 




Tube 1: 50ul OptiMEM x 17 wells = 850ul OptiMEM 
   2.8ul ivtRNA x 17 wells = 47.6ul ivtRNA 
Tube 2: 50ul OptiMEM x 17 wells = 850ul OptiMEM 
   1ul Lipofectamine x 17 wells = 17ul Lipofectamine 
The contents of Tube 2 is added to Tube 1 and incubated for 15-20 minutes. A volume of 103.8ul 
of mixture is added to each well after incubation is complete. 
       
Note* Transfections were done as forward transfections described by the Invitrogen Lipofectamine RNAiMAX 
Reagent protocol. The reverse transcription method was evaluated yielding similar results (data not shown). Due to 

















OCT4 Calibrator Evaluation 
Figure B.1 OCT4 PCR Amp/Cycle Graph of SYBR-490 
 

































SOX2 Calibrator Evaluation 
 
 





































NANOG Calibrator Evaluation 
 
 



























PAP CALIBRATOR EVALUATION 
 
Figure B.10 PAP PCR Amp/Cycle Graph for SYBR-490 
 
 




















GAPDH CALIBRATOR EVALUATION 
 
Figure B.13 GAPDH PCR Amp/Cycle Graph for SYBR-490 
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